



EPA/EPO/OEB
 D-80298 München
 + 49 89 2399-0
 TX 523 656 epmu d
 FAX + 49 89 2399-4465

Europäisches
 Patentamt

European
 Patent Office

Office européen
 des brevets

Generaldirektion 2

Directorate General 2

Direction Générale 2

Novozymes A/S
 Krogshøjvej 36
 2880 Bagsvaerd
 DANEMARK

Reference	Country
Agent 18. OKT. 2004 SLK	Short title
Action	Term

18. OCT 2004
 Lit. SLK 18. OCT 2004

Datum/Date 14.10.04

Zeichen/Ref./Réf. 4698.205-EP, SLK	Anmeldung Nr./Application No./Demande n°/Patent Nr./Patent No./Brevet n°. 97919299.4-2401/0897423
Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire Novozymes A/S	

TRANSMISSION OF THE CERTIFICATE FOR A EUROPEAN PATENT
 PURSUANT TO RULE 54 (1) EPC

The certificate for a European patent, with the
 specification annexed thereto, is enclosed herewith.

G. TERNIEDEN
 Formalities Officer
 Tel.No.: (+49-89) 2399-4440





Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Urkunde Certificate Certificat

Es wird hiermit bescheinigt, daß für die in der beigefügten Patentschrift beschriebene Erfindung ein europäisches Patent für die in der Patentschrift bezeichneten Vertragsstaaten erteilt worden ist.

It is hereby certified that a European patent has been granted in respect of the invention described in the annexed patent specification for the Contracting States designated in the specification.

Il est certifié qu'un brevet européen a été délivré pour l'invention décrite dans le fascicule de brevet ci-joint, pour les Etats contractants désignés dans le fascicule de brevet.

Europäisches Patent Nr.

European Patent No.

Brevet européen n°

0897423

Patentinhaber

Proprietor of the Patent

Titulaire du brevet

Novozymes A/S
Krogshøjvej 36
2880 Bagsvaerd/DK

Alain Pompidou

Präsident des Europäischen Patentamts
President of the European Patent Office
Président de l'Office européen des brevets

München, den
Munich, 13.10.04
Fait à Munich, le

EPA/EPO/OEB Form 2031 07.04

NZAS-0018966



(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
13.10.2004 Bulletin 2004/42

(51) Int Cl.7: **C12N 9/20, C11D 3/386**

(21) Application number: 97919299.4

(86) International application number:
PCT/DK1997/000179

(22) Date of filing: 22.04.1997

(87) International publication number:
WO 1997/041212 (06.11.1997 Gazette 1997/47)

(54) **ALKALINE LIPOLYTIC ENZYME**
ALKALISCHES, LIPOLYTISCHES ENZYM
ENZYME LIPOLYTIQUE ALCALINE

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

(30) Priority: 25.04.1996 DK 50196
25.04.1996 DK 50096

(43) Date of publication of application:
24.02.1999 Bulletin 1999/08

(83) Declaration under Rule 28(4) EPC (expert solution)

(73) Proprietor: **Novozymes A/S**
2880 Bagsvaerd (DK)

(72) Inventors:
• **HIRAYAMA, Satoshi**
Iiyama-shi, Nagano-ken 389-2255 (JP)
• **TAIRA, Rikako**
Nagareyama-shi, Chiba 270-01 (JP)
• **BORCH, Kim**
DK-3460 Birkerod (DK)
• **SANDAL, Thomas**
DK-2730 Herlev (DK)

• **HALKIER, Torben**
DK-3460 Birkerod (DK)
• **OXENBOLL, Karen, M.**
DK-2920 Charlottenlund (DK)
• **NIELSEN, Bjarne, Ronfeldt**
DK-2830 Virum (DK)

(56) References cited:
EP-A- 0 218 272 **WO-A-94/14940**
WO-A-94/14964 **WO-A-96/13578**

• **DIALOG INFORMATION SERVICE, File 357, DBA, Dialog Accession No. 060222, DBA Accession No. 87-04570, ASAHI-ELECTROCHEM., "Production of Lipase - Using Aspergillus, Beauveria, Geotrichum, Metarhizium, Mucor, Paecilomyces, Penicillium, Rhizopus or Verticillium sp"; & JP,A,61 289 884, 19-12-86.**
• **DIALOG INFORMATION SERVICE, File 55, BIOSIS PREVIEWS, Dialog Accession No. 10078966, BIOSIS No. 95078966, VAN TILBURG A-U.B. et al., "Production of Extracellular Proteins by the Biocontrol Fungus Gliocladium-Virens"; & APPL. ENVIRON. MICROBIOL., 59(1), 1993, 236-242.**

EP 0 897 423 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

TECHNICAL FIELD

5 [0001] This invention relates to an alkaline lipolytic enzyme, a detergent composition comprising the enzyme, methods of producing the enzyme, an isolated DNA sequence encoding the enzyme, a recombinant expression vector comprising the DNA sequence and cells comprising the DNA sequence or the vector,

BACKGROUND ART

10 [0002] For a number of years lipolytic enzymes have been used as detergent additives to remove lipid or fatty stains.
 [0003] Thus, the prior art suggests the use of various lipolytic enzymes with lipase or cutinase activity as detergent additives. Examples include microbial lipolytic enzymes derived from strains of *Fusarium*, e.g. *F. oxysporum* (EP 130 064) and *F. solani f. sp. pisi* (WO 90/09446), *Humicola lanuginosa* (also called *Thermomyces lanuginosus*, EP 258 068 and EP 305 216), *Pseudomonas*, e.g. *P. alcaligenes* and *P. pseudoalcaligenes* (EP 218 272), *P. cepacia* (EP 331 376),
 15 *P. mendocina* (WO 88/09367), and *Bacillus*, e.g. *B. subtilis* (Dartois et al., (1993) Biochemica et Biophysica acta 1131, 253-260), *B. stearothermophilus* (JP 64174992) and *B. pumilus* (WO 91/16422).
 [0004] It is the object of this invention to provide lipolytic enzymes having good washing performance and stability in a detergent solution.

STATEMENT OF THE INVENTION

20 [0005] Surprisingly, we have found that alkaline lipolytic enzymes can be obtained from filamentous fungi of the genera *Gliocladium*, *Verticillium* and *Trichophaea* and that the lipolytic enzymes are effective for improving the effect of detergents. The lipolytic enzymes have a good washing performance and stability in a detergent solution.

25 [0006] Full length cDNA sequences each encoding a lipolytic enzyme according to the invention were derived from three strains of *Gliocladium sp.*, *Verticillium sp.* and *Trichophaea saccata* as donor organisms. The cDNA sequences were cloned into the plasmid pYES 2.0 present in *Escherichia coli*, and the cloned *E. coli* strains were deposited by the inventors, as shown in the table below. The lipolytic enzyme encoding DNA sequence harbored in the deposited
 30 *E. coli* strain is believed to have the sequence shown in the positions and listing indicated below, and the amino acid sequence deduced therefrom is shown in the indicated positions and listing.

[0007] The information is summarized below:

Donor organism	<i>Gliocladium sp.</i>	<i>Verticillium sp.</i>	<i>T. saccata</i>
Donor strain	CBS 173.96	CBS 830.95	CBS 804.70
<i>E. coli</i> transformant	DSM 10591	DSM 10590	DSM 11298
DNA sequence listing	SEQ ID NO: 2	SEQ ID NO: 5	SEQ ID NO: 7
DNA positions	114-713	133-738	161-763
Amino acid sequence listing	SEQ ID NO: 3	SEQ ID NO: 6	SEQ ID NO: 8
Amino acid positions	1-200	1-202	1-201

35 [0008] Homologues of the above DNA and amino acid sequences were calculated by methods described later in this specification. The following homologies were found between pairs of sequences, amino acid homology at the upper right corner, and DNA homology at the lower left. (given as DNA homology / amino acid homology):

	<i>Gliocladium sp.</i>	<i>Verticillium sp.</i>	<i>T. saccata</i>
<i>Gliocladium sp.</i>	100	91	96
<i>Verticillium sp.</i>	83	100	89
<i>T. saccata</i>	92	83	100

45 [0009] Accordingly, the invention in its various aspects provides:

55 1. A lipolytic enzyme which is:

a) a polypeptide having an amino acid sequence as shown in positions 1-200 of SEQ ID NO: 3, positions 1-202

of SEQ ID NO: 6, or positions 1-201 of SEQ ID NO: 8, or
b) an analogue of the polypeptide defined in (a) which:

- 5 i) is at least 60% homologous with said polypeptide, or
 ii) is immunologically reactive with an antibody raised against said polypeptide in purified form.
2. An alkaline lipolytic enzyme which is derivable from a strain of *Gliocladium* and has a lipolytic activity at pH 10 in the absence of Ca⁺⁺ above 20% of the lipolytic activity at pH 10 in the presence of 50 mM Ca⁺⁺.
- 10 3. An alkaline lipolytic enzyme which is derivable from a strain of *Gliocladium* and gives a degree of hydrolysis above 15% on cotton/olive oil swatches in the Activity-in-Detergent (AiD) assay.
4. An alkaline lipolytic enzyme which is derivable from a strain of the genus *Verticillium* and retains more than 90% activity after 30 minutes incubation at pH 10.2, 40°C in a solution of 0.300 g/l C₁₄-C₁₆ alkyl sulfate, 0.650 g/l alcohol ethoxylate (C₁₂-C₁₄, 6 EO), 1.750 zeolite P, 0.145 g/l Na₂CO₃, 0.020 g/l acrylate/maleate copolymer and 0.050 g/l carboxymethyl cellulose.
- 15 5. An enzymatic detergent composition comprising a surfactant and the lipolytic enzyme of the invention.
- 20 6. A method of producing an alkaline lipolytic enzyme, comprising cultivation of a lipolytic enzyme-producing strain of *Gliocladium*, *Verticillium* or *Trichophaea* in a suitable nutrient medium, followed by recovery of the alkaline lipolytic enzyme.
- 25 7. A method for producing an alkaline lipolytic enzyme, comprising:
 a) isolating a DNA sequence encoding the lipolytic enzyme from a lipolytic enzyme-producing strain of *Gliocladium*, *Verticillium* or *Trichophaea*,
 b) combining the DNA fragment with appropriate expression signal(s) in an appropriate vector,
 c) transforming a suitable heterologous host organism with the vector,
30 d) cultivating the transformed host organism under conditions leading to expression of the lipolytic enzyme, and
 e) recovering the lipolytic enzyme from the culture medium.
8. An isolated DNA sequence which encodes the lipolytic enzyme of the invention.
- 35 9. An isolated, lipolytic enzyme encoding DNA sequence which comprises:
 a) the DNA sequence shown in positions 114-713 of SEQ ID NO: 2, positions 133-738 of SEQ ID NO: 5 or positions 161-763 of SEQ ID NO: 7, or
 b) an analogue of the DNA sequence defined in a) which
40 i) is at least 60% homologous with said DNA sequence, or
 ii) hybridizes with said DNA sequence at 55°C.
10. A recombinant expression vector comprising the DNA sequence of the invention.
- 45 11. A cell comprising the DNA sequence of the invention or the recombinant expression vector of aspect 10 of the invention.
12. A method of producing a lipolytic enzyme, comprising culturing the cell of aspect 11 of the invention under conditions permitting the production of the enzyme, and recovering the enzyme from the culture.
- 50 13. A biologically pure culture of a microbial strain which is *Gliocladium* sp. CBS 173.96, *Gliocladium roseum* CBS 126.96 or 127.96 or *Verticillium* sp. CBS 830.95.
- 55 14. *Escherichia coli* strain DSM 10591, DSM 10590 or DSM 11298.

Comparison with prior art

[0010] Tilburg and Thomas, Application. Environ. Microbiol., Jan. 1993, p. 236-242 describes production of lipase by *G. virens*; however, data in the article show that the prior-art lipase is not alkaline. US 4,985,365 and US 4,511,655 describe the use of culture broth of *G. roseum* IFO 5422 and *G. virens* IFO 6355 to hydrolyze carboxylic esters at acid pH. The prior art does not describe the production of lipolytic activity at alkaline pH by strains of *Gliocladium*.

[0011] The prior art describes the production of lipase by *Verticillium cinnabarinum* (also called *V. luteoalbum*) DSM 63078 (Rapp & Backhaus, Enzyme Microb. Technol., 14, 938-943 (1992)) and *Verticillium lecanii* ATCC 26854 (JP-A 61-289884). The inventors have investigated the two strains and found that they do not produce alkaline lipolytic enzyme.

[0012] The following literature describes lipase production by the genus *Verticillium* without identifying any particular strains: Kunert & Lysek, Biologica (Bratislava), 42 (3), 285-293 (1987). Leger et al., J. Invertebr. Pathol., 48, 85-95 (1986). Jackson et al., Ann. appl. Biol., 106, 39-48 (1985). Roberts et al., Mycologia, 79 (2), 265-273 (1987). Trigiano, Mycologia, 71, 908-917 (1979). However, the prior art does not describe the production of lipolytic activity at alkaline pH by strains of *Verticillium*.

[0013] A homology search was performed in nucleotide and protein databases. The highest homology for the lipolytic enzyme and DNA sequences of the invention was found with the sequence for cutinase from *Fusarium solani* f. sp. *psl*, described by C.L. Soliday et al., Proc. Natl. Acad. Sci. USA, 81, 3939-3943 (1984).

[0014] The three DNA sequences of the invention described earlier in this specification show homologies of 53-57% with the above known DNA sequence, and the three amino acid sequences of the invention described earlier show homologies of 50-53% with the above known amino acid sequence. The calculation of homology was done as described later in this specification. Using a formula given in "Current Protocols in Molecular Biology", John Wiley & Sons, 1995, hybridization of the above DNA of the invention and the closest prior-art DNA is estimated to have a melting temperature of 50°C at the hybridization conditions given later in this specification.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figs. 1-7 show pH-activity curves for lipolytic enzymes from the following strains. The pH curves were made with purified enzyme samples, except that those in Figs. 3-5 were made with crude enzyme samples.

Fig. 1: *Gliocladium* sp. NN140631

Fig. 2: *G. solani* NN102998

Fig. 3: *G. roseum* NN141784

Fig. 4: *G. aureum* NN102987

Fig. 5: *G. roseum* NN141961

Fig. 6: *Verticillium* sp. CBS 830.95

Fig. 7: *T. saccata* CBS 804.70

Fig. 8 shows the stability at various temperatures for the lipolytic enzyme from *Verticillium* sp. CBS 830.95.

DETAILED DISCLOSURE OF THE INVENTION

Lipolytic enzymes

[0016] The enzymes of this invention are lipolytic enzymes. In the present context the term "lipolytic enzyme" is intended to indicate an enzyme classified under the Enzyme Classification number E.C. 3.1.1.- (Carboxylic Ester Hydrolases) in accordance with the Recommendations (1992) of the International Union of Biochemistry and Molecular Biology (IUBMB). Lipolytic enzymes thus exhibit hydrolytic activity towards at least one of the types of ester bonds mentioned in the context of E.C. 3.1.1.

[0017] The lipolytic enzymes of the invention preferably have lipase activity (with triglycerides as substrate) and/or cutinase activity (with cutin as substrate, as described in Kolattukudy, Science, vol. 208, 30 May 1980, pp. 990-1000 and Kolattukudy in "Lipases", Borgström and Brockman ed., Elsevier 1984, pp. 471-504).

Properties of lipolytic enzyme

[0018] The invention provides lipolytic enzymes having a high activity at alkaline pH in the absence of Ca⁺⁺. Preferably, the alkaline lipolytic enzyme of the invention has a lipolytic activity at pH 10 in the absence of Ca⁺⁺ above 20% (most preferably above 50%) of the lipolytic activity at pH 10 in the presence of 50 mM Ca⁺⁺. And preferably, the lipolytic enzymes have a lipolytic activity at pH 10 in the absence of Ca⁺⁺ above 50% of the activity at pH 8 as well as pH 9 in

the absence of Ca⁺⁺. Such an enzyme can be obtained from a strain of *Gliocladium*.

[0019] Curves of lipolytic activity versus pH with and without addition of Ca⁺⁺ are shown in Figs. 1-7 for lipolytic enzymes according to the invention from the following strains: *Gliocladium sp.* NN140631, *G. solani* NN102998, *G. roseum* NN141784, *G. aureum* NN102987, *G. roseum* NN141961, *Verticillium sp.* CBS 830.95 and *T. saccata* CBS 804.70. The activity was determined by the OPID method described later in this specification (except that 60 minutes incubation was used for the data in Fig. 4). The pH curves were made with purified enzyme samples, except that those in Figs. 3-5 were made with crude enzyme samples.

[0020] Advantageously, the lipolytic enzymes of the invention are active throughout the pH range 8-10. Some preferred enzymes have increasing activity up to pH 10, indicating a pH optimum above 10.

[0021] The specific lipolytic enzyme activity is 1800 LU per A₂₈₀ for the lipolytic enzyme from *Verticillium sp.* CBS 830.95. The specific activity is expressed as lipase activity (LU) per mg of protein determined from absorption at 280 nm.

[0022] The stability is shown in Fig. 8, as expressed by the residual activity after incubating the lipolytic enzyme from *Verticillium sp.* CBS 830.95 at various temperatures for 30 minutes at pH 9. The enzyme is fully stable for 30 minutes at pH 9 at temperatures up to 50°C. This enzyme was also found to be fully stable throughout the pH range 6-10 at 25°C for 24 hours.

[0023] The invention also provides lipolytic enzymes having a high stability in a detergent solution. Preferably, the alkaline lipolytic enzyme of the invention retains more than 90% activity after 30 minutes incubation in 100 mM glycine at pH 10, 45°C or in the test detergent solution shown in the Examples at pH 10.2, 40°C. The lipolytic enzymes of the invention furthermore show a good washing performance on fatty soiling during the washing of textiles with detergent. Preferably, the alkaline lipolytic enzyme of the invention gives a degree of hydrolysis above 15% (most preferably above 20%) on cotton/olive oil swatches in the Activity-in-Detergent (AiD) assay described later in this specification. Such an enzyme can be obtained from a strain of *Verticillium*.

[0024] In this specification, lipolytic enzyme activity is expressed in units of LU, OPIDU and SLU determined by the methods described below.

Characterization of enzyme protein

[0025] The iso-electric point was determined by iso-electric focusing for some lipolytic enzymes according to the invention, as follows:

Organism	Strain No.	Iso-electric point
<i>G. solani</i>	NN102998	8.4
<i>Gliocladium sp.</i>	NN140631	9.3
<i>Verticillium sp.</i>	CBS 830.95	6.0

[0026] The molecular weight (MW) was determined by SDS-PAGE and by mass spectrometry for some lipolytic enzymes according to the invention, as follows:

Organism	Strain No.	MW (SDS-PAGE)	MW (mass spectrometry)
<i>G. solani</i>	NN102998	22 kDa	20,989 ± 21 Da
<i>Verticillium sp.</i>	CBS 830.95	22 kDa	21,107 ± 21 Da

[0027] The N-terminal sequence of the lipolytic enzyme from *G. solani* NN102998 was determined for 35 residues as shown in SEQ ID NO: 1. The complete amino acid sequence of the lipolytic enzyme from *Gliocladium sp.* CBS 173.96 was deduced from the determination of the DNA sequence and is shown in positions 1-200 of SEQ ID NO: 3. A comparison of the two amino acid sequences shows that the first 35 amino acids of the two enzymes are identical, except for position 20.

[0028] The N-terminal sequence determined for the lipolytic enzyme from *Verticillium sp.* CBS 830.95 is shown in SEQ ID NO: 4 (positions 1-29); Xaa indicates an undetermined amino acid. The complete amino acid sequence of this enzyme, as deduced from the DNA sequence, is shown in positions 1-202 of SEQ ID NO: 6.

[0029] The amino acid sequence of the lipolytic enzyme from *T. saccata* CBS 804.70 shown in positions 1-201 of SEQ ID NO: 8 was deduced from the DNA sequence, and the position of the N-terminal was deduced by a comparison with the highly homologous sequence from *Gliocladium sp.* CBS 173.96.

Lipolytic Activity by the LU Method

[0030] One Lipase Unit (LU) is the amount of enzyme which liberates 1 μmol of titratable fatty acid per minute with tributyrin as substrate and gum arabic as emulsifier at 30.0°C, pH 7.0 (phosphate buffer).

Lipase Activity by the OPID Method

[0031] The lipolytic enzyme activity without free Ca^{++} in the range pH 7-10 is tested with a substrate emulsion of olive oil: 2% PVA solution (1:3) at 40°C for 10 minutes, at a specified pH. At the end of the reaction, the reaction mixture is extracted by chloroform: methanol (1:1) at acidic conditions, and the fatty acid released during the reaction is measured by TLC-FID analysis (Iatroscan). One unit (OPIDU) is taken as the release of a μmole of fatty acid per minute.

[0032] In each test, 10 mM EDTA is used together with 200 mM of buffer (Tris-HCl buffer at pH 7 and 8, diethanol amine buffer at pH 8, 9 and 10).

Lipolytic Activity by the SLU Method

[0033] The lipolytic activity may be determined using olive oil as substrate. In this SLU method, the lipase activity is measured at 30°C and pH 9 with a stabilized olive oil emulsion (Sigma catalog No. 800-1) as the substrate, in a 5 mM Tris buffer containing 40 mM NaCl and 5 mM calcium chloride. 2.5 ml of the substrate is mixed with 12.5 ml buffer, the pH is adjusted to 9, 0.5 ml of diluted lipase sample is added, and the amount of oleic acid formed is followed by titration with a pH stat.

[0034] One SLU is the amount of lipase which liberates 1 μmole of titratable oleic acid per minute under these conditions.

Activity-In-Detergent (AID) assay

[0035] Equipment: Water bath with 150 ml beakers. Stirring is obtained by an agitator.

Lipolytic enzyme dosage: 0 & 12500 LU/l.

Substrate: 6 pieces (3.5*3.5 cm) of cotton with 6 μl olive oil

Detergent: 0.5 g/l model liquid detergent (see below) dissolved in 0,36 mM $\text{Ca}^{2+}/\text{Mg}^{2+}$ (5:1), adjusted to pH 10. 100 ml per beaker.

Method: The test swatches are added to the detergent solution, after which the samples get stirred for 60 min at 30°C. The remaining detergent on the swatches gets removed by rinsing in tap water for 15 min. The swatches are put into a flask containing 10 ml tetrahydrofuran and 6.25 μl 4 M HCl and evaporated over night, after which the samples are redissolved in tetrahydrofuran. The effect of the lipolytic enzyme is determined:

[0036] By measuring the degree of hydrolysis (% DH) by an Iatroscan TLC/FID method

Model liquid detergent:	
Component	Model detergent, % w/w
Linear alkylbenzene sulfate (LAS)	17.5
Alcohol ethoxylate (AEO)	14.4
Dodeceny/tetradeceny succinic acid (DTSA)	10
Oleic acid	3
Coconut oil	5
Mono ethanol amine (MEA)	14.5
Mono propylene glycol (MPG)	10.7
Ethanol	1,4
Phosphonate	1.0
Boric acid	0.8
Citric acid	3.9

(continued)

Model liquid detergent:	
Component	Model detergent, % w/w
Sodium chloride	0.13
Potassium chloride	0.38
Hydrochloric acid 4 M	6
Water	9.7
pH adjusted to (5 g/l)	7.7

Microbial sources

[0037] The lipolytic enzyme of this invention may be derived from an ascomycete of the order *Hypocreales* which belongs to the genus *Gliocladium*, *Verticillium* or *Trichophaea*.

[0038] The genus *Gliocladium* is characterized by having one-celled conidia formed from phialides in slimy heads. The conidiophores are distinctly penicillate. It is described in Domsch K.H. & Gams W. (1993) Compendium of Soil Fungi (reprint of 1980 edition), Volume I, IHW-Verlag, page 368.

[0039] The genus *Verticillium* is characterized by predominantly hyaline hyphae with well differentiated erect conidiophores that are verticillately branched. The branches bear whorls of slender phialides from which hyaline or brightly colored conidia are formed. The conidial masses are seen as slimy heads on top of the phialidia.

[0040] The following species and strains are preferred. Variants and mutants thereof capable of producing lipolytic enzyme may also be used in the invention.

Species name	Inventors' strain No.	Deposit number	Deposit date
<i>Gliocladium sp.</i>	NN140631	CBS 173.96	February 5, 1996
<i>G. ammoniophilum</i>	NN102992	CBS 156.70	
<i>G. aureum</i>	NN102987	IFO 9055	
<i>G. catenulatum</i>	NN100802	NRRL 1091	
<i>G. flavum</i>	NN102995	CBS 155.27	
<i>G. nigrovirens</i>	NN102996	CBS 183.30	
<i>G. roseum</i>	NN141784	CBS 126.96	January 22, 1996
	NN141961	CBS 127.96	January 22, 1996
<i>G. sagariensis</i>	NN102989	IFO 9080	
<i>G. solani</i>	NN102998	CBS 707.86	
<i>Verticillium sp.</i>	NN001755	CBS 830.95	22 December 1995
<i>T. saccata</i>	NN102806	CBS 804.70	

[0041] The deposit numbers in the above list refer to deposits made at the following deposit institutions:

CBS: Centraal Bureau voor Schimmelcultures, Oosterstraat 1, 3740 AG Baarn, Netherlands.

IFO: Institute for Fermentation, 17-85 Juso-honmachi 2-chome, Yodogawa-ku, Osaka 532, Japan.

NRRL: Agricultural Research Service Culture Collection (NRRL), 1815 North University Street, Peoria, Illinois 61604, USA.

[0042] The following strains were isolated by the inventors: *Gliocladium sp.* CBS 173.96, *G. roseum* CBS 126.96, *G. roseum* CBS 127.96 and *Verticillium sp.* CBS 830.95. These strains were deposited by the inventors according to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the deposit numbers and dates given in the table above. They were classified by standard taxonomic methods. Two strains are denoted as "sp.", indicating that they could not be identified to species level. *Verticillium sp.*

CBS 830.95 was isolated from leaf-material and thus most likely belongs to the group of saprophytic species on plant material.

Transformant *E. coli* strains

5

[0043] Expression plasmids comprising the full length cDNA sequence encoding lipolytic enzymes of the invention from three of the above strains were transformed into strains of *Escherichia coli* as indicated earlier in this specification. The transformants were deposited by the inventors according to the Budapest Treaty on the international Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38924 Braunschweig, Federal Republic of Germany, (DSM).
10 The deposit numbers and dates of the transformed *E. coli* strains were as follows:

Deposit number	Deposit date
DSM 10591	15 March 1996
DSM 10590	15 March 1996
DSM 11298	27 November 1996

15

DNA sequence

20

[0044] In this specification and claims, whenever reference is made to the lipolytic enzyme encoding part of the DNA sequence cloned into a plasmid present in a transformed *E. coli* strain, such reference is also intended to include the lipolytic enzyme encoding part of the corresponding DNA sequence listing as identified earlier in this specification. Accordingly, the terms may be used interchangeably.

25

[0045] The DNA sequence of the invention may be isolated from the deposited transformant of *Escherichia coli* by extraction of plasmid DNA by methods known in the art (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY).

30

[0046] The DNA sequence of the invention may also be isolated from a strain of the genus *Gliocladium*, *Verticillium* or *Trichophaea* producing the lipolytic enzyme of the invention or another or related organism and thus, e.g. be an allelic or species variant of the lipolytic enzyme encoding part of the DNA sequence cloned into a plasmid present in a transformant of *Escherichia coli* identified earlier in this specification.

35

[0047] Alternatively, the sequence may be constructed on the basis of the DNA sequence presented as the lipolytic enzyme encoding part of the indicated sequence listings, e.g., it may be a sub-sequence thereof, and/or be derived by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the lipolytic enzyme encoded by the DNA sequence, but which corresponds to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions which may give rise to a different amino acid sequence.

40

[0048] When carrying out nucleotide substitutions, amino acid changes are preferably of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding or activity of the protein, small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification, such as a poly-histidine tract, an antigenic epitope or a binding domain.

45

[0049] Examples of conservative substitutions are within the group of basic amino acids (such as arginine, lysine, histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine, valine), aromatic amino acids (such as phenylalanine, tryptophan, tyrosine) and small amino acids (such as glycine, alanine, serine, threonine, methionine). For a general description of nucleotide substitution, see e.g. Ford et al., (1991), Protein Expression and Purification 2, 95-107.

50

[0050] It will be apparent to persons skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active polypeptide. Amino acids essential to the activity of the polypeptide encoded by the DNA construct of the invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (cf. e.g. Cunningham and Wells, (1989), Science 244, 1081-1085). In the latter technique mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological (i.e. lipolytic enzyme) activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-enzyme interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labeling (cf. e.g. de Vos et al., (1992), Science 255, 306-312; Smith et al., (1992), J. Mol. Biol. 224, 899-904; Wlodaver et al., (1992), FEBS Lett. 309, 59-64).

55

[0051] The DNA sequence of the invention can be isolated from the transformed *E. coli* strain by extraction of DNA by methods known in the art, e.g. as described by Sambrook et al., (1989), Molecular Cloning: A Laboratory Manual.

Cold Spring Harbor Lab.; Cold Spring Harbor, NY.

[0052] The DNA sequence of the invention can also be isolated by any general method involving

- cloning, in suitable vectors, a cDNA library from any organism expected to produce the lipolytic enzyme of interest,
- 5 - transforming suitable yeast host cells with said vectors,
- culturing the host cells under suitable conditions to express any enzyme of interest encoded by a clone in the cDNA library,
- screening for positive clones by determining any lipolytic enzyme activity of the enzyme produced by such clones, and
- 10 - isolating the enzyme encoding DNA from such clones.

[0053] A general isolation method has been disclosed in WO 93/11249 or WO 94/14953, the contents of which are hereby incorporated by reference. A more detailed description of the screening method is given in the Examples below.

[0054] Alternatively, the DNA encoding a lipolytic enzyme of the invention may, in accordance with well-known procedures, conveniently be isolated from a suitable source, such as the microorganisms described above, by use of synthetic oligonucleotide probes prepared on the basis of a DNA sequence disclosed herein. For instance, a suitable oligonucleotide probe may be prepared on the basis of the lipolytic enzyme encoding part of the nucleotide sequences presented as SEQ ID NO: 2 or any suitable subsequence thereof, or on the basis of the amino acid sequence SEQ ID NO: 3.

20 Homology of DNA sequences

[0055] The DNA sequence homology referred to in this specification with claims is determined as the degree of identity between two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711; Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453). Using GAP with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous DNA sequences referred to above exhibits a degree of identity preferably of at least 70%, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, more preferably at least 97% with the lipolytic enzyme encoding part of the DNA sequence indicated earlier in the specification.

35 Hybridization

[0056] The hybridization referred to above is intended to indicate that the analogous DNA sequence hybridizes to the same probe as the DNA sequence encoding the lipolytic enzyme under certain specified conditions which are described in detail below. The oligonucleotide probe to be used is the DNA sequence corresponding to the lipolytic enzyme encoding part of the DNA sequence listings indicated earlier in the specification.

[0057] Suitable conditions for determining hybridization between a nucleotide probe and a homologous DNA or RNA sequence involves presoaking of the filter containing the DNA fragments or RNA to hybridize in 5 x SSC (standard saline citrate) for 10 min, and prehybridization of the filter in a solution of 5 x SSC (Sambrook et al. 1989), 5 x Denhardt's solution (Sambrook et al. 1989), 0.5% SDS and 100 µg/ml of denatured sonicated salmon sperm DNA (Sambrook et al. 1989), followed by hybridization in the same solution containing a random-primed (Feinberg, A. P. and Vogelstein, B. (1983) *Anal. Biochem.* 132:6-13), ³²P-dCTP-labeled (specific activity > 1 x 10⁹ cpm/µg) probe for 12 hours at ca. 45°C. The filter is then washed two times for 30 minutes in 2 x SSC, 0.5% SDS at temperatures up to 55°C, preferably up to 60°C, more preferably up to 65°C, even more preferably up to 70°C, and especially up to 75°C.

[0058] Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using a x-ray film.

50 Homology of amino acid sequences

[0059] The polypeptide homology referred to in this specification with claims is determined as the degree of identity between two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711; Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453). Using GAP with the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1, the mature part of a polypeptide encoded by an analogous DNA sequence exhibits

a degree of identity preferably of at least 70%, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, and especially at least 97% with the mature part of the amino acid sequence of lipolytic enzymes indicated earlier in this specification.

5 **Immunological cross-reactivity:**

[0060] Antibodies to be used in determining immunological cross-reactivity may be prepared by use of a purified lipolytic enzyme. More specifically, antiserum against the lipolytic enzyme of the invention may be raised by immunizing rabbits (or other rodents) according to the procedure described by N. Axelsen et al. in: A Manual of Quantitative Immunoelectrophoresis, Blackwell Scientific Publications, 1973, Chapter 23, or A. Johnstone and R. Thorpe, Immunochimistry in Practice, Blackwell Scientific Publications, 1982 (more specifically p. 27-31). Purified immunoglobulins may be obtained from the antisera, for example by salt precipitation ((NH₄)₂ SO₄), followed by dialysis and ion exchange chromatography, e.g. on DEAE-Sephadex. Immunochemical characterization of proteins may be done either by Ouchterlony double-diffusion analysis (O. Ouchterlony in: Handbook of Experimental Immunology (D.M. Weir, Ed.), Blackwell Scientific Publications, 1967, pp. 655-706), by crossed immunoelectrophoresis (N. Axelsen et al., supra, Chapters 3 and 4), or by rocket immunoelectrophoresis (N. Axelsen et al., Chapter 2).

Expression vectors

20 [0061] The expression vector of the invention may be any expression vector that is conveniently subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

[0062] In the expression vector, the DNA sequence encoding the lipolytic enzyme should be operably connected to a suitable promoter and terminator sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. The procedures used to ligate the DNA sequences coding for the lipolytic enzyme, the promoter and the terminator, respectively, and to insert them into suitable vectors are well known to persons skilled in the art (cf., for instance, Sambrook et al., (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, NY).

30 [0063] Examples of suitable promoters for use in filamentous fungus host cells are, for instance, the ADH3 promoter (McKnight et al., The EMBO J. 4 (1985), 2093 - 2099) or the *tpiA* promoter. Examples of other useful promoters are those derived from the gene encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral α -amylase, *Aspergillus niger* acid stable α -amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*gluA*), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase or *Aspergillus nidulans* acetamidase.

Host cells

40 [0064] The host organism is preferably a eukaryotic cell, in particular a fungal cell, such as a yeast cell or a filamentous fungal cell. Preferred filamentous fungi include *Aspergillus*, *Fusarium* or *Trichoderma*, most preferably *A. niger*, *A. oryzae*, *F. graminearum*, *F. sambucinum*, *F. cerealis*, *T. harzianum* or *T. reesei*. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known per se. Protoplasts may be prepared as described in WO 95/02043, p. 16, line 21 - page 17, line 12, which is hereby incorporated by reference. The use of *Aspergillus* as a host microorganism is described in EP 238 023 (Novo Nordisk A/S), the contents of which are hereby incorporated by reference. The host cell may also be a yeast cell, e.g. a strain of *Saccharomyces*, in particular *Saccharomyces cerevisiae*, *Saccharomyces kluyveri* or *Saccharomyces uvarum*, a strain of *Schizosaccharomyces* such as *Schizosaccharomyces pombe*, a strain of *Hansenula*, *Pichi*, *Yarrowia* (such as *Yarrowia lipolytica*) or *Kluyveromyces* (such as *Kluyveromyces lactis*).

Production of lipolytic enzyme

55 [0065] The lipolytic enzyme of the invention may be produced by cultivation of one of the microorganisms described above in a suitable nutrient medium, containing carbon and nitrogen sources and inorganic salts, followed by recovery of the lipolytic enzyme. An alternative method of producing the lipolytic enzyme of the invention comprises transforming a suitable host cell with a DNA sequence encoding the enzyme, cultivating the transformed organism under conditions permitting the production of the enzyme, recovering the enzyme from the culture.

[0066] The medium used to culture the microorganism or transformed host cells may be any conventional medium suitable for growing the organism in question. The expressed lipolytic enzyme may conveniently be secreted into the culture medium and may be recovered therefrom by well-known procedures including separating the cells from the medium by centrifugation or filtration, precipitating proteinaceous components of the medium by means of a salt such as ammonium sulfate, followed by chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

Application of lipolytic enzyme

[0067] The lipolytic enzyme of the invention may be used in conventional applications of lipolytic enzyme, particularly at a high pH, e.g. in laundry and dishwash detergents, in institutional and industrial cleaning and in leather processing.

[0068] The lipolytic enzymes of the invention can also be used for interesterification, for total hydrolysis of fats and oils and in optical isomer resolution processes.

15 Detergent additive

[0069] According to the invention, the lipolytic enzyme may typically be used as an additive in a detergent composition. This additive is conveniently formulated as a non-dusting granulate, a stabilized liquid, a slurry or a protected enzyme.

20 [0070] A suitable activity range for a detergent additive containing the lipolytic enzyme of this invention is 5,000-100,000 OPIDU/g (OPID measured at pH 9) or 0.01-100 mg pure enzyme protein per g of the additive.

Detergent

25 [0071] The lipolytic enzyme of the invention may be incorporated in concentrations conventionally employed in detergents. The detergent composition of the invention may comprise lipolytic enzyme in an amount corresponding to 10-50,000 LU per gram of detergent, preferably 20-5,000 LU/g. The detergent may be dissolved in water to produce a wash liquor containing lipolytic enzyme in an amount corresponding to 25-15,000 LU per liter of wash liquor. The amount of lipolytic enzyme protein may be 0.001-10 mg per gram of detergent or 0.001-100 mg per liter of wash liquor.

30 Detergent Compositions

[0072] According to the invention, the lipolytic enzyme may typically be a component of a detergent composition. As such, it may be included in the detergent composition in the form of a non-dusting granulate, a stabilized liquid, or a protected enzyme. Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 (both to Novo Industri A/S) and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethylene glycol, PEG) with mean molecular weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in patent GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

45 [0073] The detergent composition of the invention may be in any convenient form, e.g. as powder, granules, paste or liquid. A liquid detergent may be aqueous, typically containing up to 70% water and 0-30% organic solvent, or non-aqueous.

[0074] The detergent composition comprises one or more surfactants, each of which may be anionic, nonionic, cationic, or zwitterionic. The detergent will usually contain 0-50% of anionic surfactant such as linear alkylbenzene sulfonate (LAS), alpha-olefin sulfonate (AOS), alkyl sulfate (fatty alcohol sulfate) (AS), alcohol ethoxysulfate (AEOS or AES), secondary alkane sulfonates (SAS), alpha-sulfo fatty acid methyl esters, alkyl- or alkenylsuccinic acid, or soap. It may also contain 0-40% of nonionic surfactant such as alcohol ethoxylate (AEO or AE), carboxylated alcohol ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside, alkylidimethylamine oxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide (e.g. as described in WO 92/06154).

55 [0075] The detergent composition may additionally comprise one or more other enzymes, such as amylase, cutinase, protease, cellulase, peroxidase, and oxidase, e.g., laccase.

[0076] The detergent may contain 1-65% of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, citrate, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetri-

aminepentaacetic acid (DTMPA), alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst). The detergent may also be unbuil, i.e. essentially free of detergent builder.

[0077] The detergent may comprise one or more polymers. Examples are carboxymethyl cellulose (CMC), poly(vinyl pyrrolidone) (PVP), polyethylene glycol (PEG), poly(vinyl alcohol) (PVA), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

[0078] The detergent may contain a bleaching system which may comprise a H_2O_2 source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetythylenediamine (TAED) or nonanoyloxybenzene sulfonate (NOBS). Alternatively, the bleaching system may comprise peroxy acids of, e.g., the amide, imide, or sulfone type.

[0079] The enzymes of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g. a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative such as, e.g., an aromatic borate ester, and the composition may be formulated as described in, e.g., WO 92/19709 and WO 92/19708.

[0080] The detergent may also contain other conventional detergent ingredients such as, e.g., fabric conditioners including clays, foam boosters, suds suppressors, anticorrosion agents, soil-suspending agents, anti-soil-redeposition agents, dyes, bactericides, optical brighteners, or perfume.

[0081] The pH (measured in aqueous solution at use concentration) will usually be neutral or alkaline, e.g. in the range of 7-11.

[0082] Particular forms of detergent compositions within the scope of the invention include:

- 1) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

Linear alkylbenzene sulfonate (calculated as acid)	7-12%
Alcohol ethoxysulfate (e.g. C_{12-18} alcohol, 1-2 EO) or alkyl sulfate (e.g. C_{16-18})	1-4%
Alcohol ethoxylate (e.g. C_{14-15} alcohol, 7 EO)	5 - 9%
Sodium carbonate (as Na_2CO_3)	14 - 20%
Soluble silicate (as $Na_2O, 2SiO_2$)	2 - 6%
Zeolite (as $NaAlSiO_4$)	15 - 22%
Sodium sulfate (as Na_2SO_4)	0 - 6%
Sodium citrate/citric acid (as $C_6H_5Na_3O_7/C_6H_8O_7$)	0 - 15%
Sodium perborate (as $NaBO_3 \cdot H_2O$)	11 - 18%
TAED	2-6%
Carboxymethyl cellulose	0 - 2%
Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	0 - 3%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
Minor ingredients (e.g. suds suppressors, perfume, optical brightener, photobleach)	0-5%

- 2) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

Linear alkylbenzene sulfonate (calculated as acid)	6-11%
Alcohol ethoxysulfate (e.g. C_{12-18} alcohol, 1-2 EO) or alkyl sulfate (e.g. C_{16-18})	1 - 3%
Alcohol ethoxylate (e.g. C_{14-15} alcohol, 7 EO)	5 - 9%
Sodium carbonate (as Na_2CO_3)	15 - 21 %
Soluble silicate (as $Na_2O, 2SiO_2$)	1 - 4%
Zeolite (as $NaAlSiO_4$)	24 - 34%
Sodium sulfate (as Na_2SO_4)	4-10%
Sodium citrate/citric acid (as $C_6H_5Na_3O_7/C_6H_8O_7$)	0-15%

(continued)

Carboxymethyl cellulose	0 - 2%
Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	1 - 6%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
Minor ingredients (e.g. suds suppressors, perfume)	0 - 5%

3) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

Linear alkylbenzene sulfonate (calculated as acid)	5 - 9%
Alcohol ethoxylate (e.g. C ₁₂₋₁₅ alcohol, 7 EO)	7 - 14%
Soap as fatty acid (e.g. C ₁₆₋₂₂ fatty acid)	1 - 3%
Sodium carbonate (as Na ₂ CO ₃)	10 - 17%
Soluble silicate (as Na ₂ O, 2SiO ₂)	3 - 9%
Zeolite (as NaAlSiO ₄)	23 - 33%
Sodium sulfate (as Na ₂ SO ₄)	0 - 4%
Sodium perborate (as NaBO ₃ ·H ₂ O)	8 - 16%
TAED	2-8%
Phosphonate (e.g. EDTMPA)	0 - 1%
Carboxymethyl cellulose	0 - 2%
Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	0 - 3%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
Minor ingredients (e.g. suds suppressors, perfume, optical brightener)	0 - 5%

4) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

Linear alkylbenzene sulfonate (calculated as acid)	8 - 12%
Alcohol ethoxylate (e.g. C ₁₂₋₁₅ alcohol, 7 EO)	10 - 25%
Sodium carbonate (as Na ₂ CO ₃)	14 - 22%
Soluble silicate (as Na ₂ O, 2SiO ₂)	1 - 5%
Zeolite (as NaAlSiO ₄)	25 - 35%
Sodium sulfate (as Na ₂ SO ₄)	0 - 10%
Carboxymethyl cellulose	0-2%
Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	1 - 3%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1 %
Minor ingredients (e.g. suds suppressors, perfume)	0 - 5%

5) An aqueous liquid detergent composition comprising

Linear alkylbenzene sulfonate (calculated as acid)	15 - 21 %
Alcohol ethoxylate (e.g. C ₁₂₋₁₅ alcohol, 7 EO or C ₁₂₋₁₅ alcohol, 5 EO)	12 - 18%
Soap as fatty acid (e.g. oleic acid)	3 - 13%
Alkenylsuccinic acid (C ₁₂₋₁₄)	0 - 13%

(continued)

5	Aminoethanol	8 - 18%
	Citric acid	2 - 8%
	Phosphonate	0 - 3%
	Polymers (e.g. PVP, PEG)	0 - 3%
	Borate (as B_4O_7)	0 - 2%
10	Ethanol	0 - 3%
	Propylene glycol	8-14%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
15	Minor ingredients (e.g. dispersants, suds suppressors, perfume, optical brightener)	0-5%

6) An aqueous structured liquid detergent composition comprising

20	Linear alkylbenzene sulfonate (calculated as acid)	15 - 21 %
	Alcohol ethoxylate (e.g. C_{12-15} alcohol, 7 EO, or C_{12-15} alcohol, 5 EO)	3 - 9%
	Soap as fatty acid (e.g. oleic acid)	3 - 10%
	Zeolite (as $NaAlSi_3O_8$)	14 - 22%
25	Potassium citrate	9 - 18%
	Borate (as B_4O_7)	0 - 2%
	Carboxymethyl cellulose	0 - 2%
	Polymers (e.g. PEG, PVP)	0 - 3%
30	Anchoring polymers such as, e.g., lauryl methacrylate/acrylic acid copolymer; molar ratio 25:1; MW 3800	0 - 3%
	Glycerol	0 - 5%
35	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1 %
	Minor ingredients (e.g. dispersants, suds suppressors, perfume, optical brighteners)	0 - 5%

7) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

40	Fatty alcohol sulfate	5 - 10%
	Ethoxylated fatty acid monoethanolamide	3 - 9%
	Soap as fatty acid	0 - 3%
45	Sodium carbonate (as Na_2CO_3)	5 - 10%
	Soluble silicate (as $Na_2O \cdot 2SiO_2$)	1 - 4%
	Zeolite (as $NaAlSi_3O_8$)	20 - 40%
	Sodium sulfate (as Na_2SO_4)	2-8%
50	Sodium perborate (as $NaBO_3 \cdot H_2O$)	12 - 18%
	TAED	2-7%
	Polymers (e.g. maleic/acrylic acid copolymer, PEG)	1 - 5%
55	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
	Minor ingredients (e.g. optical brightener, suds suppressors, perfume)	0 - 5%

8) A detergent composition formulated as a granulate comprising

Linear alkylbenzene sulfonate (calculated as acid)	8 - 14%
Ethoxylated fatty acid monoethanolamide	5 - 11 %
Soap as fatty acid	0-3%
Sodium carbonate (as Na_2CO_3)	4 - 10%
Soluble silicate (as $\text{Na}_2\text{O} \cdot 2\text{SiO}_2$)	1 - 4%
Zeolite (as NaAlSiO_4)	30 - 50%
Sodium sulfate (as Na_2SO_4)	3 - 11 %
Sodium citrate (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$)	5 - 12%
Polymers (e.g. PVP, maleic/acrylic acid copolymer, PEG)	1 - 5%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
Minor ingredients (e.g. suds suppressors, perfume)	0 - 5%

9) A detergent composition formulated as a granulate comprising

Linear alkylbenzene sulfonate (calculated as acid)	6 - 12%
Nonionic surfactant	1 - 4%
Soap as fatty acid	2 - 6%
Sodium carbonate (as Na_2CO_3)	14 - 22%
Zeolite (as NaAlSiO_4)	18 - 32%
Sodium sulfate (as Na_2SO_4)	5 - 20%
Sodium citrate (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$)	3 - 8%
Sodium perborate (as $\text{NaBO}_3 \cdot \text{H}_2\text{O}$)	4-9%
Bleach activator (e.g. NOBS or TAED)	1 - 5%
Carboxymethyl cellulose	0 - 2%
Polymers (e.g. polycarboxylate or PEG)	1 - 5%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
Minor ingredients (e.g. optical brightener, perfume)	0 - 5%

10) An aqueous liquid detergent composition comprising

Linear alkylbenzene sulfonate (calculated as acid)	15 - 23%
Alcohol ethoxysulfate (e.g. C_{12-15} alcohol, 2-3 EO)	8 - 15%
Alcohol ethoxylate (e.g. C_{12-15} alcohol, 7 EO, or C_{12-15} alcohol, 5 EO)	3 - 9%
Soap as fatty acid (e.g. lauric acid)	0 - 3%
Aminoethanol	1 - 5%
Sodium citrate	5 - 10%
Hydrotrope (e.g. sodium toluene sulfonate)	2 - 6%
Borate (as B_4O_7)	0 - 2%
Carboxymethyl cellulose	0 - 1 %
Linear alkylbenzene sulfonate (calculated as acid)	15 - 23%

(continued)

Ethanol	1-3%
Propylene glycol	2 - 5%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
Minor ingredients (e.g. polymers, dispersants, perfume, optical brighteners)	0 - 5%

11) An aqueous liquid detergent composition comprising

Linear alkylbenzene sulfonate (calculated as acid)	20 - 32%
Alcohol ethoxylate (e.g. C ₁₂₋₁₅ alcohol, 7 EO, or C ₁₂₋₁₅ alcohol, 5 EO)	6 - 12%
Aminoethanol	2 - 6%
Citric acid	8 - 14%
Borate (as B ₄ O ₇)	1 - 3%
Polymer (e.g. maleic/acrylic acid copolymer, anchoring polymer such as, e.g., lauryl methacrylate/acrylic acid copolymer)	0 - 3%
Glycerol	3 - 8%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1 %
Minor ingredients (e.g. hydrotropes, dispersants, perfume, optical brighteners)	0 - 5%

12) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

Anionic surfactant (linear alkylbenzene sulfonate, alkyl sulfate, alpha-olefin sulfonate, alpha-sulfo fatty acid methyl esters, alkane sulfonates, soap)	25 - 40%
Nonionic surfactant (e.g. alcohol ethoxylate)	1 - 10%
Sodium carbonate (as Na ₂ CO ₃)	8 - 25%
Soluble silicates (as Na ₂ O, 2SiO ₂)	5 - 15%
Sodium sulfate (as Na ₂ SO ₄)	0 - 5%
Zeolite (as NaAlSiO ₄)	15 - 28%
Sodium perborate (as NaBO ₃ ·4H ₂ O)	0 - 20%
Bleach activator (TAED or NOBS)	0 - 5%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1 %
Minor ingredients (e.g. perfume, optical brighteners)	0 - 3%

13) Detergent formulations as described in 1) - 12) wherein all or part of the linear alkylbenzene sulfonate is replaced by (C₁₂-C₁₈) alkyl sulfate.

14) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

(C ₁₂ -C ₁₈) alkyl sulfate	9 - 15%
Alcohol ethoxylate	3 - 6%
Polyhydroxy alkyl fatty acid amide	1 - 5%
Zeolite (as NaAlSiO ₄)	10 - 20%
Layered disilicate (e.g. SK56 from Hoechst)	10 - 20%
Sodium carbonate (as Na ₂ CO ₃)	3-12%
Soluble silicate (as Na ₂ O, 2SiO ₂)	0 - 6%

(continued)

Sodium citrate	4 - 8%
Sodium percarbonate	13 - 22%
TAED	3 - 8%
Polymers (e.g. polycarboxylates and PVP=)	0-5%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
Minor ingredients (e.g. optical brightener, photo bleach, perfume, suds suppressors)	0-5%

15) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

(C ₁₂ -C ₁₈) alkyl sulfate	4 - 8%
Alcohol ethoxylate	11 - 15%
Soap	1-4%
Zeolite MAP or zeolite A	35 - 45%
Sodium carbonate (as Na ₂ CO ₃)	2 - 8%
Soluble silicate (as Na ₂ O,2SiO ₂)	0 - 4%
Sodium percarbonate	13 - 22%
TAED	1 - 8%
Carboxymethyl cellulose	0 - 3%
Polymers (e.g. polycarboxylates and PVP)	0 - 3%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
Minor ingredients (e.g. optical brightener, phosphonate, perfume)	0 - 3%

16) Detergent formulations as described in 1) - 15) which contain a stabilized or encapsulated peracid, either as an additional component or as a substitute for already specified bleach systems.

17) Detergent compositions as described in 1), 3), 7), 9) and 12) wherein perborate is replaced by percarbonate.

18) Detergent compositions as described in 1), 3), 7), 9), 12), 14) and 15) which additionally contain a manganese catalyst. The manganese catalyst may, e.g., be one of the compounds described in "Efficient manganese catalysts for low-temperature bleaching", *Nature* 369, 1994, pp. 637-639.

19) Detergent composition formulated as a nonaqueous detergent liquid comprising a liquid nonionic surfactant such as, e.g., linear alkoxylated primary alcohol, a builder system (e.g. phosphate), enzyme and alkali. The detergent may also comprise anionic surfactant and/or a bleach system.

[0083] The lipolytic enzyme of the invention may be incorporated in concentrations conventionally employed in detergents. It is at present contemplated that, in the detergent composition of the invention, the lipolytic enzyme may be added in an amount corresponding to 0.00001-1 mg (calculated as pure enzyme protein) of lipolytic enzyme per liter of wash liquor.

EXAMPLES

Materials And Methods

[0084] The following materials and methods were used in the Examples that follow:

Microorganisms:

[0085] Yeast strain: The *Saccharomyces cerevisiae* strain used was W3124 (MAT α ; ura 3-52; leu 2-3, 112; his 3-D200; pep 4-1137; prc1::HIS3; prb1:: LEU2; cir⁺).

E. coli strain: DH10B (available, e.g., from Life Technologies)

Plasmids:

[0086] The *Aspergillus* expression vector pHD414 is a derivative of the plasmid p775 (described in EP 238 023). The construction of pHD414 is further described in WO 93/11249.

5 pYES 2.0 (available, e.g., from invitrogen)

General molecular biology methods:

10 [0087] Unless otherwise mentioned the DNA manipulations and transformations were performed using standard methods of molecular biology (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., and Cutting, S. M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons, 1990).

Expression cloning in yeast

[0088] Expression cloning in yeast was done as comprehensively described by H. Dalboege et al. (H. Dalboege et al Mol. Gen. Genet (1994) 243:253-260.; WO 93/11249; WO 94/14953), which are hereby incorporated as reference.

20 [0089] Extraction of total RNA, cDNA synthesis, Mung bean nuclease treatment, Blunt-ending with T4 DNA polymerase, and Construction of libraries were done according to the references mentioned above.

Identification of positive clones:

25 [0090] The transformants are plated on SC agar containing 2% glucose and incubated for 3 days at 30°C. A cellulose acetate filter (OE 67, Schleicher & Schuell) is placed on top of the cells and then transferred to plates containing SC agar and 2% galactose with the cells on the top of the filter. After 3 days of incubation at 30°C the filter with cells is transferred to substrate plates. Positive clones are identified as colonies surrounded by a green zone.

Characterization of positive clones:

30 [0091] The positive clones are obtained as single colonies, the cDNA inserts were amplified directly from the yeast colony using biotinylated polylinker primers, purified by magnetic beads (Dynabead M-280, Dynal) system and characterized individually by sequencing the 5'-end of each cDNA clone using the chain-termination method (Sanger et al. (1977) Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467) and the Sequenase system (United States Biochemical).

35

Isolation of a cDNA gene for expression in *Aspergillus*:

[0092] A lipolytic enzyme-producing yeast colony is inoculated into 20 ml YPD broth in a 50 ml glass test tube. The tube is shaken for 2 days at 30°C. The cells are harvested by centrifugation for 10 min. at 3000 rpm.

40 [0093] DNA is isolated according to WO 94/14953 and dissolved in 50 µl water. The DNA is transformed into *E. coli* by standard procedures. Plasmid DNA is isolated from *E. coli* using standard procedures, and analyzed by restriction enzyme analysis. The cDNA insert is excised using appropriate restriction enzymes and ligated into an *Aspergillus* expression vector.

Transformation of *Aspergillus oryzae* or *Aspergillus niger*

50 [0094] 100 µl of protoplast suspension is mixed with 5-25 µg of the appropriate DNA in 10 µl of STC (1.2 M sorbitol, 10 mM Tris-HCl, pH = 7.5, 10 mM CaCl₂). Protoplasts are mixed with p3SR2 (an *A. nidulans* amdS gene carrying plasmid). The mixture is left at room temperature for 25 minutes. 0.2 ml of 60% PEG 4000 (BDH 29576), 10 mM CaCl₂ and 10 mM Tris-HCl, pH 7.5 is added and carefully mixed (twice) and finally 0.85 ml of the same solution is added and carefully mixed. The mixture is left at room temperature for 25 minutes, spun at 2500 g for 15 minutes and the pellet is resuspended in 2 ml of 1.2 M sorbitol. After one more sedimentation the protoplasts are spread on minimal plates (Cove, Biochem. Biophys. Acta 113 (1966) 51-56) containing 1.0 M sucrose, pH 7.0, 10 mM acetamide as nitrogen source and 20 mM CsCl to inhibit background growth. After incubation for 4-7 days at 37°C spores are picked and spread for single colonies. This procedure is repeated and spores of a single colony after the second reisolation is stored as a defined transformant.

55

Test of *A. oryzae* transformants

[0095] Each of the transformants is inoculated in 10 ml of YPM (cf. below) and propagated. After 2-5 days of incubation at 30°C, the supernatant is removed. The lipolytic activity is identified by applying 10 µl supernatant to 4 mm diameter holes punched out in agar plates containing 0.1 M glycine pH 9, 0.1 M CaCl₂, 1% Triton X-100, 0.5% olive oil. Lipolytic activity is indicated by the formation of a turbid halo.

Fed batch fermentation:

[0096] Fed batch fermentation was performed in a medium comprising maltodextrin as a carbon source, urea as a nitrogen source and yeast extract. The fed batch fermentation was performed by inoculating a shake flask culture of *A. oryzae* host cells in question into a medium comprising 3.5% of the carbon source and 0.5% of the nitrogen source. After 24 hours of cultivation at pH 7.0 and 34°C the continuous supply of additional carbon and nitrogen sources were initiated. The carbon source was kept as the limiting factor and it was secured that oxygen was present in excess. The fed batch cultivation was continued for 4 days.

Media

[0097] YPD: 10 g yeast extract, 20 g peptone, H₂O to 900 ml. Autoclaved, 100 ml 20% glucose (sterile filtered) added.

YPM: 10 g yeast extract, 20 g peptone, H₂O to 900 ml. Autoclaved, 100 ml 20% maltodextrin (sterile filtered) added.

10 x Basal salt: 75 g yeast nitrogen base, 113 g succinic acid, 68 g NaOH, H₂O ad 1000 ml, sterile filtered.

SC-URA: 160 ml 10 x Basal salt, 28 ml 20% casamino acids without vitamins; 10 ml 1% tryptophan, H₂O ad 900 ml, autoclaved, 3.6 ml 5% threonine and 100 ml 20% glucose or 20% galactose added.

SC-agar: SC-URA, 20 g/l agar added.

SC-variant agar: 20 g agar, 20 ml 10 x Basal salt, H₂O ad 900 ml, autoclaved

Substrate plates: Petri dish containing 100 mM glycine, pH 9.0, 1% brilliant green solution, 2.5 mM CaCl₂, 0.6% olive oil, 0.036% polyvinyl alcohol (MW 70,000-100,000, Sigma P-1763)

PEG 4000 (polyethylene glycol, molecular weight = 4,000) (BDH, England)

Ingredient	Composition of medium (g/l)					
	Agar30	YS-2	Gli	MT-C	NOMO 16	YS-25
Peptone	6	10	10	5	6	10
Pepticase	4				4	
Soybean powder				30		
Corn steep powder				5		
Yeast extract	3	10		1	3	10
Meat extract	1.5				1.5	
Glucose	1	20		10	1	5
NH ₄ NO ₃				2.5		
K ₂ HPO ₄		5	5	4		5
MgSO ₄ ·7H ₂ O		1	1	0.1		1
Olive oil	20		20			
Corn oil				10 or 20		
Soybean oil						20
Sorbitan monostearate					20	
pH adjusted to	7.4	6.5	7.0	7.0	7.4	6.5

Example 1

Lipase production from strains of *Gliocladium* and *Trichophaea*

5 [0098] Each of the *Gliocladium* strains shown in the table below was used for lipolytic enzyme production by a seed culture followed by a main culture. The seed culture was made by cultivation on YS-2 medium for 2 days at 27°C, and the main culture was made at 27°C using the medium and culture time shown below. At the end of the main culture, the cells were removed and the yield of lipolytic activity was measured using the LU and SLU assay methods.

10

Species	Strain	Main culture		Lipase activity	
		Medium	Days	LU/ml	SLU/ml
<i>G. catenulatum</i>	NN100802	MT-O	5	2.3	-
15 <i>G. aureum</i>	NN102987	Agar30	3	2.4	1.7
<i>G. sagariensis</i>	NN102989	MT-C	3	0.7	1.2
<i>G. ammoniophilum</i>	NN102992	Agar30	3	3.0	2.7
<i>G. flavum</i>	NN102995	Gli	3	2.1	1.5
20 <i>G. nigrovitens</i>	NN102996	Gil	3	3.2	0.9
<i>G. solani</i>	NN102998	Agar30	5	36.0	-
<i>Gliocladium sp.</i>	NN140631	Agar30	3	4.4	-
25 <i>G. roseum</i>	NN141784	Agar30	5	2.6	-
<i>G. roseum</i>	NN141961	MR-10	3	9.0	-
<i>T. saccata</i>	NN102806	YS-25	3	5.2	-

30 [0099] All the above strains were seen to produce lipolytic enzyme. A particularly high yield was found by cultivation of *G. solani*.

Example 2

35 Activity of lipolytic enzymes from *Gliocladium* and *Trichophaea* at various pH

[0100] The cell-free culture broths from Example 1 were tested for lipolytic enzyme activity at pH 6.0, 8.5 and 10.0 without the addition of Ca⁺⁺ and at pH 10 with addition of Ca⁺⁺. The plate test described in Example 11 of WO 88/02775 (corresponding to JP-W 1-501120) was used.

40

Species	Strain	Lipase activity			
		pH 6	pH 8.5	pH 10	pH 10 + Ca ⁺⁺
<i>G. catenulatum</i>	NN100802	-	2	2	2
45 <i>G. aureum</i>	NN102987	1	1	1	1
<i>G. sagariensis</i>	NN102989	1	2	2	2
<i>G. ammoniophilum</i>	NN102992	1	2	2	2
<i>G. flavum</i>	NN102995	2	3	2	2
50 <i>G. nigrovirens</i>	NN102996	1	1	1	1
<i>G. solani</i>	NN102998	2	2	3	3
<i>Gliocladium sp.</i>	NN140631	-	2	2	-
55 <i>G. roseum</i>	NN141784	-	2	2	-
<i>G. roseum</i>	NN141961	-	1	1	-

(continued)

Species	Strain	Lipase activity			
		pH 6	pH 8.5	pH 10	pH 10 + Ca ⁺⁺
<i>T. saccata</i>	NN102806	-	2	2	-

[0101] It is seen that in this semi-quantitative test, all the above lipase preparations show nearly the same activity in the range pH 6-10, with and without calcium addition.

Example 3

Production of lipolytic enzyme from *Gliocladium sp.*

[0102] A seed culture was prepared by inoculating *Gliocladium sp.* CBS 173.96 from a slant of PDA (product of Difco) to one shake flask with shaking for 2 days at 27°C. A main culture was prepared by using the seed culture to inoculate 50 shake flasks with 100 ml of NOMO 16 for 5 days at 27°C with shaking.

[0103] 3,000 ml of cell-free broth with a lipase activity of 11 LU/ml was recovered after removal of the cell mass, that was directly employed for the purification.

Example 4

Purification of lipolytic enzyme from *Gliocladium sp.*

[0104] 0.5% CHAPS was added to the culture broth from Example 3. This was centrifuged at 45,000 rpm for 1 hour and filtered on a 0.8 µm filter. The filtrate was applied onto a gel filtration column (Superdex, product of Pharmacia) using 50 mM Tris-HCl buffer (pH 8.5 with 0.2 M NaCl).

Example 5

Production of lipolytic enzyme from *G. solani*

[0105] A seed culture was prepared by inoculating *G. solani* CBS 707.86 from a slant of PDA (product of Difco) to two shake flasks with shaking for 2 days at 27°C. A main culture was prepared by using the seed culture to inoculate 50 shake flasks with 100 ml of Agar 30 for 5 days at 27°C with shaking. 4,900 ml of cell-free broth with a lipase activity of 49 LU/ml was recovered after removal of the cell mass. This was deionized and free-dried to obtain 10.2 g of powder sample with a lipase activity of 15,700 LU/g.

Example 6

Purification of lipolytic enzyme from *G. solani*

[0106] The lipolytic enzyme was purified by 2 steps, hydrophobic interaction and gel fixation. More specifically, the purification was performed as follows.

[0107] The powder sample from Example 5 was dissolved in 3 M ammonium acetate including 0.5% 3[3-Cholamidopropyl]dimethylammonio]-1-propanesulfonate (CHAPS) and centrifuged at 18,000 rpm for 20 minutes. The supernatant was filtered with 0.2 µm filter and applied onto Butyl Toyopearl column chromatography (62 x 200 mm). After unbound materials were washed out by 3 M ammonium acetate and then the column was washed by 50 mM sodium carbonate buffer (pH 10.0) including 0.5% CHAPS. Lipolytic activity was eluted by H₂O. The eluted lipolytic enzyme was applied onto gel filtration column (26 x 600 mm). The applied volume was 3 ml and the eluent was 35 mM sodium carbonate buffer (pH 10.0) including 0.3% CHAPS. The flow rate was 3 ml/min. The lipolytic enzyme was eluted around 225 ml.

[0108] A molecular weight of 36 kDa was calculated from the gel filtration.

[0109] Fractions containing lipolytic activity were pooled and dialyzed/concentrated by ultra-filtration. A molecular weight of the lipolytic enzyme of 22 kD was calculated from SDS-PAGE. An iso-electric point between 8.15 and 8.45 was found by IEF-PAGE.

Example 7

Production of lipolytic enzyme from *Verticillium sp.*

5 [0110] Seed cultures of *Verticillium sp.* CBS 830.95 were produced in 500 ml shake flasks containing 150 ml medium of the following composition:

Corn steep liquor: 12 g/l
Glucose: 24 g/l

10 To each flask is added 0.5 ml of oil and 0.5 g of CaCO₃.
pH is adjusted to 5.5 before autoclavation.

[0111] The flasks were inoculated with spore suspensions from slants, using 10 ml per shake flask.

15 [0112] After 2 days at 26°C at 200 rpm, the seed culture was used for inoculation of shake flasks containing 150 ml of the following medium:

Peptone	6 g/l
Peptidase	4 g/l
Yeast extract	3 g/l
Beef extract	1.5 g/l
Dextrose	1 g/l
Olive oil	10 g/l
pH is adjusted to 7.3-7.4 before autoclavation	

[0113] Each flask was inoculated with 4 ml seed culture. The flasks were incubated at 26°C at 200 rpm for 4 days.

[0114] Two flasks yielded respectively 6.3 LU/ml and 7.6 LU/ml.

[0115] 50 flasks resulted in 4.7 l of broth which was purified.

Example 8

Purification of lipolytic enzyme from *Verticillium sp.*

35 [0116] 4 l of culture broth obtained as in Example 1 with an activity of 4.4 LU/ml was purified by the following procedure.

[0117] Decyl Agarose (50 ml): The culture broth was filtered and applied on a Decyl Agarose column previously equilibrated in 10 mM Tris/0.25 M NaCl, pH 7. Bound proteins were eluted with 50% ethanol. Yield: 75%.

40 [0118] Q Sepharose (25 ml): The Decyl Agarose fraction was applied on a Q Sepharose column previously equilibrated in 10 mM H₃BO₃/KCl, pH 10 after adjusting pH to 10. Activity was eluted from 0-0.25 M NaCl using a linear gradient. Yield: 50%.

[0119] Concentration: Desalting was carried out on G-25, followed by speed vacuum freeze drying. Yield: 60%.

Example 9

Wash performance of lipolytic enzyme

[0120] Lipolytic enzyme of the invention was compared to prior-art enzymes in the following washing test:

50 [0121] A lipolytic enzyme according to this invention (from *G. solani* NN102998) was tested by the above AiD assay and compared to a prior-art enzyme: Lipolase® (a lipase derived from *Humicola lanuginosa*).

	Lipase	% hydrolysis on olive oil
Invention	<i>G. solani</i> NN102998	23
Prior art	Lipolase	8
Blank	None	1

[0122] It is seen that the wash effect of the lipase of this invention is far superior to the prior art.

Example 10

5 Stability of lipolytic enzyme in detergent solution

[0123] The purified lipolytic enzyme from Example 2 was incubated for 30 minutes in each of the solutions shown below. The lipase activity was measured before and after the incubation, and the stability was expressed as % residual activity. Results:

100 mM glycine, pH 10, 45°C	97%
Test detergent (see below), pH 10.2, 40°C	99%

[0124] The above results demonstrate an excellent stability at alkaline pH, even in the presence of detergent.

[0125] The test detergent solution had the following composition (in g/l):

Alkyl sulfate (C ₁₄ -C ₁₆)	0.300
Alcohol ethoxylate (C ₁₂ -C ₁₄ , 6 EO)	0.650
Zeolite P	1.750
Na ₂ CO ₃	0.145
Acrylate/maleate copolymer	0.020
Carboxymethyl cellulose	0.050

25 Example 11

Cloning and expression of lipolytic enzymes

[0126] In this example, lipolytic enzymes from *Gliocladium sp.* CBS 173, *Verticillium sp.* CBS 830.95 and *T. saccata* CBS 804.70 as donor organisms were cloned and expressed, using the method for "Expression cloning in yeast" described previously in this specification.

[0127] mRNA was isolated from the donor organism, cultivated essentially as in the main culture of a preceding example with agitation to ensure sufficient aeration. Mycelia were harvested after 3-5 days' growth, immediately frozen in liquid nitrogen and stored at -80°C. A library therefrom, consisting of approx. 9×10^5 individual clones was constructed in *E. coli* as described with a vector background of 1%. Plasmid DNA from some of the pools was transformed into yeast, and 50-100 plates containing 250-400 yeast colonies were obtained from each pool.

[0128] Lipolytic enzyme-positive colonies were identified and isolated as described above. cDNA inserts were amplified directly from the yeast colonies and characterized as described in the Materials and Methods section above. The DNA sequence of the cDNA encoding the lipolytic enzyme was determined. The DNA sequence, the corresponding amino acid sequence and the lipolytic enzyme encoding region are shown in the sequence listings identified earlier in this specification.

[0129] Total DNA was isolated from a yeast colony and plasmid DNA was rescued by transformation of *E. coli* as described above. In order to express the lipolytic enzyme in *Aspergillus*, the DNA was digested with appropriate restriction enzymes, size fractionated on gel, and a fragment corresponding to the lipolytic enzyme gene was purified. The gene was subsequently ligated to pHD414 and digested with appropriate restriction enzymes. The resulting plasmid from each of the three donor organisms is denoted pA2L 123, pA2L 114 and pC1L 160, respectively.

[0130] After amplification of the DNA in *E. coli* the plasmid was transformed into *Aspergillus oryzae* as described above.

[0131] Each of the transformants were tested for lipolytic enzyme activity as described above. Some of the transformants had lipolytic enzyme activity which was significantly larger than the *Aspergillus oryzae* background. This demonstrates efficient expression of the lipolytic enzyme in *Aspergillus oryzae*.

SEQUENCE LISTING

[0132]

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Novo Nordisk A/S
- (B) STREET: Novo Alle
- (C) CITY: Bagsvaerd
- (E) COUNTRY: Denmark
- (F) POSTAL CODE (ZIP): DK-2880
- (G) TELEPHONE: +45-4444-8888
- (H) TELEFAX: +45-4449-3256

(ii) TITLE OF INVENTION: Alkaline Lipolytic Enzyme

(iii) NUMBER OF SEQUENCES: 8

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: G.solani
- (B) STRAIN: NN102998

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 1:

Glu Asp Ser Ile Gly Ile Ser Ser Val Leu Val Arg Asp Glu Leu Arg
 1 5 10 15
 Asn Gly Gly Gly Ala Cys Pro Lys Ala Ile Leu Ile Phe Ala Arg Gly
 20 25 30
 Thr Met Glu
 35

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 914 base pairs
- (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Gliocladium sp.
 (B) STRAIN: NN140631

10

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION:21..713

15

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
 (B) LOCATION:114..713

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

25	TGATTTTCA ACTCTGCATC ATG AAG TTC CTC TAC GTC GTC CAG ACC TTG	50
	Met Lys Phe Leu Tyr Val Val Gln Thr Leu	
	-31 -30 -25	
30	ATC GCC CTC GCC TTG GCT AGG CCA TTG CCT GAG ACG GCT GTG GAA GTT	98
	Ile Ala Leu Ala Leu Ala Arg Pro Leu Pro Glu Thr Ala Val Glu Val	
	-20 -15 -10	
35	GAC CTG CAG AAC CGA GAA GAT TCT ATC GGC ATA TCC TCT GTC CTT GTG	146
	Asp Leu Gln Asn Arg Glu Asp Ser Ile Gly Ile Ser Ser Val Leu Val	
	-5 1 5 10	
40	CGT GAC GAG CTG CGC AAT GGC GGC AGC GCG TGC CCC AAG GCC ATT CTC	194
	Arg Asp Glu Leu Arg Asn Gly Gly Ser Ala Cys Pro Lys Ala Ile Leu	
	15 20 25	
45	ATC TTT GCT CGA GGC ACA ATG GAG CTG GAT AAC ATG GGC TTA TTG GTC	242
	Ile Phe Ala Arg Gly Thr Met Glu Leu Asp Asn Met Gly Leu Leu Val	
	30 35 40	
50	GGG CCA GCT CTT GCA GGT GGC TTA GAG GGC ATC TTG GGT TCG AAC AAC	290
	Gly Pro Ala Leu Ala Gly Gly Leu Glu Gly Ile Leu Gly Ser Asn Asn	
	45 50 55	

50

55

5 CTC TGG GTT CAA GGG GTG GGT GGC CAA TAT GCC GCC AAC CTT GAG GGC 338
 Leu Trp Val Gln Gly Val Gly Gly Gln Tyr Ala Ala Asn Leu Glu Gly
 60 65 70 75

 AAT CTA TTT CCA GAT GGA ACA CCT CCT AAA GCC ATC CAG GAG ATG CTT 386
 Asn Leu Phe Pro Asp Gly Thr Pro Pro Lys Ala Ile Gln Glu Met Leu
 80 85 90

 10 AGC CTG CTC CAA TTG GCG GAC ACC AAG TGC CCA AAC TCT AAG ATT GTT 434
 Ser Leu Leu Gln Leu Ala Asp Thr Lys Cys Pro Asn Ser Lys Ile Val
 95 100 105

 15 ACA GGG GGT TAT AGC CAA GGT GCT GCA CTC GTG GCC GCT GCT ATT CGC 482
 Thr Gly Gly Tyr Ser Gln Gly Ala Ala Leu Val Ala Ala Ile Arg
 110 115 120

 GAT GTC AAG GCT TCC ATT CGA CAA AAG ATT GTG GGA ACC GTA CTC TTT 530
 Asp Val Lys Ala Ser Ile Arg Gln Lys Ile Val Gly Thr Val Leu Phe
 125 130 135

 GGG TAT ACT AAA AAC AAA CAG AGG AAC GGA CAG GTA GAA AAC TAC TCA 578
 Gly Tyr Thr Lys Asn Lys Gln Arg Asn Gly Gln Val Glu Asn Tyr Ser
 140 145 150 155

 ACT GAT CGG CTC CGG GTT TAC TGT AAC CTC GGA GAC TTG ATT TGT GAA 626
 Thr Asp Arg Leu Arg Val Tyr Cys Asn Leu Gly Asp Leu Ile Cys Glu
 160 165 170

 30 GGG ACC TTG ATT GTT CTA CCA CCA CAT CTT CTT TAT GGA GTC CAG GCT 674
 Gly Thr Leu Ile Val Leu Pro Pro His Leu Leu Tyr Gly Val Gln Ala
 175 180 185

 35 GCT GGT CCA GCT GCC CAG TTC CTC GCC AGC AAG ATC AAT TAATTTTCT 723
 Ala Gly Pro Ala Ala Gln Phe Leu Ala Ser Lys Ile Asn
 190 195 200

 40 TGATCAATGC ATGGCAGAAT GCTGCCATGT ACTCAGATAT GGATAGGAGA GATCATATAT 783

 GGACTATATA TAGTAGCTCT GCCGCATCTG TCGAAAGTTT TGATATTCTT TCGTTCGTTG 843

 TTAGGGCTGA CTTATTCTTG AGATGAATAA AAAAAGATCT GTATAAAGAG AAAAAAAAAA 903

 45 AAAAAAAAA A 914

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 231 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

5 Met Lys Phe Leu Tyr Val Val Gln Thr Leu Ile Ala Leu Ala Leu Ala
 -31 -30 -25 -20
 Arg Pro Leu Pro Glu Thr Ala Val Glu Val Asp Leu Gln Asn Arg Glu
 -15 -10 -5 1
 10 Asp Ser Ile Gly Ile Ser Ser Val Leu Val Arg Asp Glu Leu Arg Asn
 5 10 15
 Gly Gly Ser Ala Cys Pro Lys Ala Ile Leu Ile Phe Ala Arg Gly Thr
 15 20 25 30
 Met Glu Leu Asp Asn Met Gly Leu Leu Val Gly Pro Ala Leu Ala Gly
 35 40 45
 20 Gly Leu Glu Gly Ile Leu Gly Ser Asn Asn Leu Trp Val Gln Gly Val
 50 55 60 65
 Gly Gly Gln Tyr Ala Ala Asn Leu Glu Gly Asn Leu Phe Pro Asp Gly
 25 70 75 80
 Thr Pro Pro Lys Ala Ile Gln Glu Met Leu Ser Leu Leu Gln Leu Ala
 85 90 95
 30 Asp Thr Lys Cys Pro Asn Ser Lys Ile Val Thr Gly Gly Tyr Ser Gln
 100 105 110
 Gly Ala Ala Leu Val Ala Ala Ala Ile Arg Asp Val Lys Ala Ser Ile
 35 115 120 125
 Arg Gln Lys Ile Val Gly Thr Val Leu Phe Gly Tyr Thr Lys Asn Lys
 130 135 140 145
 40 Gln Arg Asn Gly Gln Val Glu Asn Tyr Ser Thr Asp Arg Leu Arg Val
 150 155 160
 Tyr Cys Asn Leu Gly Asp Leu Ile Cys Glu Gly Thr Leu Ile Val Leu
 45 165 170 175
 Pro Pro His Leu Leu Tyr Gly Val Gln Ala Ala Gly Pro Ala Ala Gln
 180 185 190
 50 Phe Leu Ala Ser Lys Ile Asn
 195 200
 55

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Verticillium sp.
- (B) STRAIN: CBS 830.95

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Glu Asp Ser Phe Gly Ile Ser Ser Val Leu Val Arg Asp Glu Leu Ile
 1 5 10 15

Asn Gly Gly Gly Ala Xaa Pro Lys Ala Ile Leu Ile Phe
 20 25

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 869 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Verticillium sp.
- (B) STRAIN: CBS 830.95

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION:43..738

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION:133..738

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CTCAATTCGT GAAAGTCTGA GATCAATTTT CAAGTTTGCA TT ATG AAG TTC CTT 54
 Met Lys Phe Leu
 -30

5

TAC ATT CTT CAG ACC CTA GCT ACC CTT GCG CTA GCC ACT CCC GTA CCT 102
 Tyr Ile Leu Gln Thr Leu Ala Thr Leu Ala Leu Ala Thr Pro Val Pro
 -25 -20 -15

10

GAG ACG GTA CCA GAG AGT GAC CTG CAA AGT CGA GAA GAT TCT TTT GGT 150
 Glu Thr Val Pro Glu Ser Asp Leu Gln Ser Arg Glu Asp Ser Phe Gly
 -10 -5 1 5

15

ATA TCT TCT GTT CTC GTG CGT GAT GAA TTG ATC AAT GGT GGC GGC GCT 198
 Ile Ser Ser Val Leu Val Arg Asp Glu Leu Ile Asn Gly Gly Gly Ala
 10 15 20

20

TGC CCC AAG GCT ATC CTC ATC TTT GCT CGA GGA ACG ATA GAA CTT GAT 246
 Cys Pro Lys Ala Ile Leu Ile Phe Ala Arg Gly Thr Ile Glu Leu Asp
 25 30 35

25

AAC ATG GGC TTA TTG GTT GGG CCA CCT CTT GCA GAC GGT CTA TCG GGT 294
 Asn Met Gly Leu Leu Val Gly Pro Pro Leu Ala Asp Gly Leu Ser Gly
 40 45 50

30

ATC TTG GGT TCA AAA AAC CTC TGG GTC CAA GGC GTG GGT GGC CAA TAT 342
 Ile Leu Gly Ser Lys Asn Leu Trp Val Gln Gly Val Gly Gly Gln Tyr
 55 60 65 70

35

GCT GCA AGC TTG GAG GGT AAT CTC TTT CCG GAT GGG ACC CCT CCT CAA 390
 Ala Ala Ser Leu Glu Gly Asn Leu Phe Pro Asp Gly Thr Pro Pro Gln
 75 80 85

40

GCC ATC CAG GAG ATG ATT ACA TTG CTT CAA TTG GCG GAT ACT AAA TGT 438
 Ala Ile Gln Glu Met Ile Thr Leu Leu Gln Leu Ala Asp Thr Lys Cys
 90 95 100

45

CCA AAC TCC AAG ATT GTC ACT GGG GGA TAT AGT CAA GGT GCT GCT CTC 486
 Pro Asn Ser Lys Ile Val Thr Gly Gly Tyr Ser Gln Gly Ala Ala Leu
 105 110 115

50

GTG GCC GCA GCA ATT CGG GAT GTC AAG GCT TCG ATC CGA CAG AAG ATT 534
 Val Ala Ala Ala Ile Arg Asp Val Lys Ala Ser Ile Arg Gln Lys Ile
 120 125 130

55

GTA GGA ACT GTA CTG TTC GGG TAC TCC AAA AAC AAA CAG AGG AAC GGT 582
 Val Gly Thr Val Leu Phe Gly Tyr Ser Lys Asn Lys Gln Arg Asn Gly
 135 140 145 150

CAG GTA GAA AAC TAC TCT AAT GAC CGA CTC CGA GTT TAT TGC AAC CCT 630
 Gln Val Glu Asn Tyr Ser Asn Asp Arg Leu Arg Val Tyr Cys Asn Pro
 155 160 165

5 GGG GAT TTA ATT TGC GAG GGG ACC TTG ATT GTT CTG CCA GTG CAC CTC 678
 Gly Asp Leu Ile Cys Glu Gly Thr Leu Ile Val Leu Pro Val His Leu
 170 175 180
 10 CTT TAT GGA AAC CAA GCT TCT GGT CCT GCA GCA CAA TTC CTC GCT AGT 726
 Leu Tyr Gly Asn Gln Ala Ser Gly Pro Ala Ala Gln Phe Leu Ala Ser
 185 190 195
 15 AAG ATC AAT TCT TAGTTGAATT GTAGCCAACC GGATATGGCT GGGGATGGGC 778
 Lys Ile Asn Ser
 200
 15 CCAATCGTAA CCTATATAAT AGGCTTCATG CCATGTCTTA TTGCTAATAT ACGAAAAGAA 838
 ATTCTGAATA CATAAAAAAA AAAAAAAAAA A 869

20

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 232 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: protein

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

40

45

50

55

Met Lys Phe Leu Tyr Ile Leu Gln Thr Leu Ala Thr Leu Ala Leu Ala
 -30 -25 -20 -15

5 Thr Pro Val Pro Glu Thr Val Pro Glu Ser Asp Leu Gln Ser Arg Glu
 -10 -5 1

10 Asp Ser Phe Gly Ile Ser Ser Val Leu Val Arg Asp Glu Leu Ile Asn
 5 10 15

Gly Gly Gly Ala Cys Pro Lys Ala Ile Leu Ile Phe Ala Arg Gly Thr
 20 25 30

15 Ile Glu Leu Asp Asn Met Gly Leu Leu Val Gly Pro Pro Leu Ala Asp
 35 40 45 50

20 Gly Leu Ser Gly Ile Leu Gly Ser Lys Asn Leu Trp Val Gln Gly Val
 55 60 65

Gly Gly Gln Tyr Ala Ala Ser Leu Glu Gly Asn Leu Phe Pro Asp Gly
 70 75 80

25 Thr Pro Pro Gln Ala Ile Gln Glu Met Ile Thr Leu Leu Gln Leu Ala
 85 90 95

30 Asp Thr Lys Cys Pro Asn Ser Lys Ile Val Thr Gly Gly Tyr Ser Gln .
 100 105 110

35 Gly Ala Ala Leu Val Ala Ala Ala Ile Arg Asp Val Lys Ala Ser Ile
 115 120 125 130

40 Arg Gln Lys Ile Val Gly Thr Val Leu Phe Gly Tyr Ser Lys Asn Lys
 135 140 145

Gln Arg Asn Gly Gln Val Glu Asn Tyr Ser Asn Asp Arg Leu Arg Val
 150 155 160

45 Tyr Cys Asn Pro Gly Asp Leu Ile Cys Glu Gly Thr Leu Ile Val Leu
 165 170 175

Pro Val His Leu Leu Tyr Gly Asn Gln Ala Ser Gly Pro Ala Ala Gln
 180 185 190

50 Phe Leu Ala Ser Lys Ile Asn Ser
 195 200

55 (2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 999 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

10

(A) ORGANISM: Trichophaea saccata
(B) STRAIN: CBS 804.70

(ix) FEATURE:

15

(A) NAME/KEY: CDS
(B) LOCATION:68..763

(ix) FEATURE:

20

(A) NAME/KEY: mat_peptide
(B) LOCATION:161..763

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

25

CTTGGTACCG AGCTCGGATC CGAATTCGCA CAACGGGTTT CCGACTTTTG ATTCCAACG 60

CTGCATC ATG AAG TTC CTC TAC GCC GTC CAG ACC TTA ATC GCC TTT GCA 109

30

Met Lys Phe Leu Tyr Ala Val Gln Thr Leu Ile Ala Phe Ala
-31 -30 -25 -20

35

40

45

50

55

CTG GCT ACG CCA GTG CCC GAG ACG GCT GTA GCA GTT GAT CTG CAG AAT 157
 Leu Ala Thr Pro Val Pro Glu Thr Ala Val Ala Val Asp Leu Gln Asn
 -15 -10 -5
 5
 CGA GAA GAT TCT ATC GGC ATA TCC TCT GTC CTT GTG CGT GAT GAA CTG 205
 Arg Glu Asp Ser Ile Gly Ile Ser Ser Val Leu Val Arg Asp Glu Leu
 1 5 10 15
 10
 CGC AAT GGC GGC GGC GCG TGT CCC AAG GCC ATT CTC ATC TTT GCT AGA 253
 Arg Asn Gly Gly Gly Ala Cys Pro Lys Ala Ile Leu Ile Phe Ala Arg
 20 25 30
 15
 GGT ACA ATG GAG CTG GAT AAC ATG GGC TTA TTA GTC GGG CCA GCT CTT 301
 Gly Thr Met Glu Leu Asp Asn Met Gly Leu Leu Val Gly Pro Ala Leu
 35 40 45
 20
 GCA GGT GGC TTA GAG GCT ATG CTG GGT TCA AAT AAC CTC TGG GTC CAA 349
 Ala Gly Gly Leu Glu Ala Met Leu Gly Ser Asn Asn Leu Trp Val Gln
 50 55 60
 GGT GTA GGT GGC CAA TAT GCT GCC AAT CTC GAG GGC AAT CTA TTT CCA 397
 Gly Val Gly Gly Gln Tyr Ala Ala Asn Leu Glu Gly Asn Leu Phe Pro
 25 65 70 75
 GAT GGA ACA CCT CCC AAA GCC ATC CAG GAG ATG CTT AGT CTG CTC CAA 445
 Asp Gly Thr Pro Pro Lys Ala Ile Gln Glu Met Leu Ser Leu Leu Gln
 30 80 85 90 95
 TTA GCG GAC ACC AAG TGT CCA AAC TCT AAG ATT GTC ACA GGG GGG TAT 493
 Leu Ala Asp Thr Lys Cys Pro Asn Ser Lys Ile Val Thr Gly Gly Tyr
 100 105 110
 35
 AGC CAA GGC GCT GCA CTC GTA GCC GCT GCT ATT CGC GAC GTC AAG GCT 541
 Ser Gln Gly Ala Ala Leu Val Ala Ala Ala Ile Arg Asp Val Lys Ala
 115 120 125
 40
 TCC ATT CGA CAA AAG ATT GTA GGA ACT GTA CTC TTT GGG TAC ACC AAA 589
 Ser Ile Arg Gln Lys Ile Val Gly Thr Val Leu Phe Gly Tyr Thr Lys
 130 135 140
 AAC AAA CAG AAG AAC GGA CAG GTA GAA AAC TAC TCA ACT GAT CGA CTC 637
 Asn Lys Gln Lys Asn Gly Gln Val Glu Asn Tyr Ser Thr Asp Arg Leu
 45 145 150 155
 CGG GTT TAT TGC AAC GCC GGA GAC TTG ATT TGT CAA GGG ACC TTG ATT 685
 Arg Val Tyr Cys Asn Ala Gly Asp Leu Ile Cys Gln Gly Thr Leu Ile
 50 160 165 170 175
 GTT CTG CCA GCG CAT CTT CTT TAC GGA GAT CAG GCT GCT GGT CCA GCA 733
 Val Leu Pro Ala His Leu Leu Tyr Gly Asp Gln Ala Ala Gly Pro Ala
 180 185 190
 55

GCC CAG TTC CTT GCC AGC AAG ATC AGT TCA TAATTGCTTG ATCAACGCAT 783
 Ala Gln Phe Leu Ala Ser Lys Ile Ser Ser
 195 200

5 CACAGATTGC TGCCATGCAC CCATATATGG ATAGGAGAGA TCAAATATGG ACCTTACATA 843

GTCGCTCTAC CGCATCTGCT AAGAATATTT GATATTCCTT CGTTCCTTCT TAAGGCTAAT 903

10 GTATCCTCGA GATGGATGAT TAAGATCAST ATAAAGAGAT GTAACAATTT ATACAGGCCGA 963

TCTAGGTAGA TACTAAGACT ACATTTAAGT GTGAAA 999

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 232 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Lys Phe Leu Tyr Ala Val Gln Thr Leu Ile Ala Phe Ala Leu Ala
 -31 -30 -25 -20

Thr Pro Val Pro Glu Thr Ala Val Ala Val Asp Leu Gln Asn Arg Glu
 -15 -10 -5 1

35 Asp Ser Ile Gly Ile Ser Ser Val Leu Val Arg Asp Glu Leu Arg Asn
 5 10 15

40 Gly Gly Gly Ala Cys Pro Lys Ala Ile Leu Ile Phe Ala Arg Gly Thr
 20 25 30

Met Glu Leu Asp Asn Met Gly Leu Leu Val Gly Pro Ala Leu Ala Gly
 35 40 45

45 Gly Leu Glu Ala Met Leu Gly Ser Asn Asn Leu Trp Val Gln Gly Val
 50 55 60 65

50 Gly Gly Gln Tyr Ala Ala Asn Leu Glu Gly Asn Leu Phe Pro Asp Gly
 70 75 80

Thr Pro Pro Lys Ala Ile Gln Glu Met Leu Ser Leu Leu Gln Leu Ala
 85 90 95

55 Asp Thr Lys Cys Pro Asn Ser Lys Ile Val Thr Gly Gly Tyr Ser Gln
 100 105 110

Gly Ala Ala Leu Val Ala Ala Ala Ile Arg Asp Val Lys Ala Ser Ile
 115 120 125

5 Arg Gln Lys Ile Val Gly Thr Val Leu Phe Gly Tyr Thr Lys Asn Lys
 130 135 140 145

10 Gln Lys Asn Gly Gln Val Glu Asn Tyr Ser Thr Asp Arg Leu Arg Val
 150 155 160

Tyr Cys Asn Ala Gly Asp Leu Ile Cys Gln Gly Thr Leu Ile Val Leu
 165 170 175

15 Pro Ala His Leu Leu Tyr Gly Asp Gln Ala Ala Gly Pro Ala Ala Gln
 180 185 190

20 Phe Leu Ala Ser Lys Ile Ser Ser
 195 200

25

30

35

40

45

50

55

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13b1s)

5
10
15
20
25
30
35
40
45
50
55

A. The indications made below relate to the microorganism referred to in the description on page 10, lines 15-20 to page 11, lines 3-8.

B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet

Name of depositary institution
Centraal Bureau voor Schimmelcultures

Address of depositary institution (including postal code and country)
Oosterstraat 1, 3740 AG Baarn, Netherlands

Date of deposit 5 February, 1996	Accession Number CBS 173.96
--	---------------------------------------


C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet

Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No 71.

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer 	Authorized officer

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)**

5	<p>A. The indications made below relate to the microorganism referred to in the description on page <u>10</u>, lines <u>15-20</u> to page <u>11</u>, lines <u>3-8</u>.</p>	
10	<p>B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></p>	
	<p>Name of depositary institution</p> <p>Centraal Bureau voor Schimmelcultures</p>	
15	<p>Address of depositary institution (including postal code and country)</p> <p>Oosterstraat 1, 3740 AG Baarn, Netherlands</p>	
20	<p>Date of deposit</p> <p style="text-align: center;">22 December, 1995</p>	<p>Accession Number</p> <p style="text-align: center;">CBS 830.95</p>
	<p>C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/></p>	
25	<p>Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No 71.</p>	
30	<p>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)</p>	
35	<p>E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)</p>	
40	<p>The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")</p>	

45	<p>For receiving Office use only</p>	<p>For International Bureau use only</p>
	<p><input checked="" type="checkbox"/> This sheet was received with the international application</p>	<p><input type="checkbox"/> This sheet was received by the International Bureau on:</p>
50	<p>Authorized officer</p> <p style="text-align: center;"><i>[Signature]</i></p>	<p>Authorized officer</p>

FORM PCT/RO/134 (JULY 1992)

55

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)**

5

A. The indications made below relate to the microorganism referred to in the description on page 10, lines 15-20 to page 11, lines 3-8.

10

B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet

Name of depositary institution

Centraal Bureau voor Schimmelcultures

15

Address of depositary institution (including postal code and country)

Oosterstraat 1, 3740 AG Baam, Netherlands

20

Date of deposit <p style="text-align: center;">January 22, 1996</p>	Accession Number <p style="text-align: center;">CBS 126.96</p>
--	---

25

C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet

Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No 71.

30

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

35

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

40

<p style="text-align: center;">For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer </p>	<p style="text-align: center;">For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau or:</p> <p>Authorized officer</p>
---	--

45

50

55

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13b/s)

5
10
15
20
25
30
35
40
45
50
55

<p>A. The indications made below relate to the microorganism referred to in the description on page <u>10</u>, lines <u>15-20</u> to page <u>11</u>, lines <u>3-8</u>.</p>	
<p>B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></p>	
<p>Name of depositary institution Centraal Bureau voor Schimmelcultures</p>	
<p>Address of depositary institution (including postal code and country) Oosterstraat 1, 3740 AG Baarn, Netherlands</p>	
<p>Date of deposit January 22, 1996</p>	<p>Accession Number CBS 127.96</p>
<p>C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/></p>	
<p>Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No 71.</p>	
<p>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)</p>	
<p>E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)</p>	
<p>The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. 'Accession Number of Deposit')</p>	

<p>For receiving Office use only</p>
<p><input checked="" type="checkbox"/> This sheet was received with the international application</p>
<p>Authorized officer <i>[Signature]</i></p>

<p>For International Bureau use only</p>
<p><input type="checkbox"/> This sheet was received by the International Bureau on:</p>
<p>Authorized officer</p>

FORM PCT/RO/134 (JULY 1992)

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

5

A. The indications made below relate to the microorganism referred to in the description on page 11, lines 15-22.

10

B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet

15

Name of depositary institution

Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

Address of depositary institution (including postal code and country)

Mascheroder Weg 1b, D-38124 Braunschweig, Germany

20

Date of deposit	Accession Number
15 March, 1996	DSM 10590

25

C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet

30

Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No 71.

35

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

40

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

45

For receiving Office use only

This sheet was received with the international application

Authorized officer

Erhard Fiedler

50

For International Bureau use only

This sheet was received by the International Bureau etc.

Authorized officer

55

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

5
10
15
20
25
30
35
40
45
50
55

A. The indications made below relate to the microorganism referred to in the description on page <u>11</u> , lines <u>15-22</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Germany	
Date of deposit <p style="text-align: center;">15 March, 1996</p>	Accession Number <p style="text-align: center;">DSM 10591</p>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No 71.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. 'Accession Number of Deposit')	
<p style="text-align: center;">For receiving Office use only</p> <div style="border: 1px solid black; padding: 5px;"> <input checked="" type="checkbox"/> This sheet was received with the international application </div> Authorized officer 	<p style="text-align: center;">For International Bureau use only</p> <div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> This sheet was received by the International Bureau on </div> Authorized officer

Form PCT/RO/134 (July 1992)

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

5
10
15
20
25
30
35
40
45
50
55

A. The indications made below relate to the microorganism referred to in the description on page <u>11</u> lines <u>15-22</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Germany	
Date of deposit <p style="text-align: center;">27 November, 1986</p>	Accession Number <p style="text-align: center;">DSM 11298</p>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No 71.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

For receiving Office use only	
<input checked="" type="checkbox"/>	This sheet was received with the international application
Authorized officer 	

For International Bureau use only	
<input type="checkbox"/>	This sheet was received by the International Bureau or:
Authorized officer	

Form PCT/RO/134 (July 1992)

Claims

1. An alkaline lipolytic enzyme which is:

a) a polypeptide having an amino acid sequence as shown in positions 1-200 of SEQ ID NO: 3, positions 1-202 of SEQ ID NO: 6, or positions 1-201 of SEQ ID NO: 8, or
 b) an analogue of the polypeptide defined in (a) which:

- 5 i) is at least 60% homologous with said polypeptide, or
 ii) is immunologically reactive with an antibody raised against said polypeptide in purified form.
2. The lipolytic enzyme of the preceding claim, which is obtainable from a microorganism, preferably a filamentous fungus, more preferably a strain of *Gliocladium*, *Verticillium* or *Trichophaea* (preferably *T. saccata*).
- 10 3. The lipolytic enzyme of claim 2 which is derivable from a strain of *Gliocladium* and has a lipolytic activity at pH 10 in the absence of Ca⁺⁺ above 20% of the lipolytic activity at pH 10 in the presence of 50 mM Ca⁺⁺.
- 15 4. The lipolytic enzyme of claim 2 or 3 which is derivable from a strain of *Gliocladium* and gives a degree of hydrolysis above 15% on cotton/olive oil swatches in the Activity-in-Detergent (AiD) assay.
- 20 5. The lipolytic enzyme of any preceding claim, wherein the strain is *Gliocladium* sp. CBS 173.96 or belongs to *G. ammoniophilum*, *G. aureum*, *G. catenulatum*, *G. flavum*, *G. nigrovirens*, *G. roseum*, *G. sagariensis* or *G. solani*, preferably *Gliocladium* sp. CBS 173.96, *G. ammoniophilum* CBS 156.70, *G. aureum* IFO 9055, *G. catenulatum* NRRL 1091, *G. flavum* CBS 155.27, *G. nigrovirens* CBS 183.30, *G. roseum* CBS 126.96, *G. roseum* CBS 127.96, *G. sagariensis* IFO 9080 or *G. solani* CBS 707.86.
- 25 6. The lipolytic enzyme of claim 2 which is derivable from a strain of the genus *Verticillium* and retains more than 90% activity after 30 minutes incubation at pH 10.2, 40°C in a solution of 0.300 g/l C14-C16 alkyl sulfate, 0.650 g/l alcohol ethoxylate (C12-C14, 6 EO), 1.750 zeolite P, 0.145 g/l Na₂CO₃, 0.020 g/l acrylate/maleate copolymer and 0.050 g/l carboxymethyl cellulose.
- 30 7. The lipolytic enzyme of the preceding claim wherein the strain is *Verticillium* sp. CBS 830.95.
8. The lipolytic enzyme of any preceding claim which has lipase and/or cutinase activity.
9. The lipolytic enzyme of any preceding claim in the form of an enzymatic detergent additive which is a non-dusting granulate, a stabilized liquid, a slurry, or a protected enzyme.
- 35 10. An enzymatic detergent composition comprising a surfactant and the lipolytic enzyme of any preceding claim.
- 40 11. A method of producing an alkaline lipolytic enzyme, comprising cultivation of a lipolytic enzyme-producing strain of *Gliocladium*, *Verticillium* or *Trichophaea* in a suitable nutrient medium, followed by recovery of the alkaline lipolytic enzyme.
- 45 12. The method of the preceding claim, wherein the strain is *Gliocladium* sp. CBS 173.96 or belongs to *G. ammoniophilum*, *G. aureum*, *G. catenulatum*, *G. flavum*, *G. nigrovirens*, *G. roseum*, *G. sagariensis* or *G. solani*, preferably *Gliocladium* sp. CBS 173.96, *G. ammoniophilum* CBS 156.70, *G. aureum* IFO 9055, *G. catenulatum* NRRL 1091, *G. flavum* CBS 155.27, *G. nigrovirens* CBS 183.30, *G. roseum* CBS 126.96, *G. roseum* CBS 127.96, *G. sagariensis* IFO 9080 or *G. solani* CBS 707.86.
13. The method of claim 11, wherein the strain is a strain of *Verticillium*, and is preferably *Verticillium* sp. CBS 830.95.
- 50 14. The method of claim 11, wherein the strain is a strain of *Trichophaea*, preferably *T. saccata*, most preferably *T. saccata* CBS 804.70.
15. A method for producing an alkaline lipolytic enzyme, comprising:
- 55 a) isolating a DNA sequence encoding the lipolytic enzyme from a lipolytic enzyme-producing strain of *Gliocladium*, *Verticillium* or *Trichophaea*,
 b) combining the DNA fragment with appropriate expression signal(s) in an appropriate vector,
 c) transforming a suitable heterologous host organism with the vector,
 d) cultivating the transformed host organism under conditions leading to expression of the lipolytic enzyme, and

- e) recovering the lipolytic enzyme from the culture medium.
16. The method of the preceding claim, wherein the host organism is a eukaryotic cell, in particular a fungal cell, such as a yeast cell or a filamentous fungal cell, preferably a strain of *Aspergillus*, more preferably *A. oryzae*.
17. The method of claim 15 or 16, wherein the DNA sequence is isolated by a method comprising:
- a) cloning, in suitable vectors, a cDNA library from the lipolytic enzyme-producing strain of *Gliocladium*, *Verticillium* or *Trichophaea*,
 - b) transforming suitable yeast host cells with said vectors,
 - c) cultivating the transformed yeast host cells under suitable conditions to express the alkaline lipolytic enzyme,
 - d) screening for positive clones by determining the lipolytic enzyme activity expressed in step (c).
18. The method of any of claims 15-17, wherein the lipolytic enzyme producing strain is *Gliocladium* sp. CBS 173.96 or belongs to *G. ammoniophilum*, *G. aureum*, *G. catenulatum*, *G. flavum*, *G. nigrovirens*, *G. roseum*, *G. sagariensis* or *G. solani*, preferably *Gliocladium* sp. CBS 173.96, *G. ammoniophilum* CBS 156.70, *G. aureum* IFO 9055, *G. catenulatum* NRRL 1091, *G. flavum* CBS 155.27, *G. nigrovirens* CBS 183.30, *G. roseum* CBS 126.96, *G. roseum* CBS 127.96, *G. sagariensis* IFO 9080 or *G. solani* CBS 707.86.
19. The method of any of claims 15-17, wherein the lipolytic enzyme producing, strain belongs to *Verticillium* and is preferably *Verticillium* sp. CBS 830.95.
20. The method of any of claims 15-17 wherein the lipolytic enzyme producing strain belongs to *Trichophaea*, preferably *T. saccata*, most preferably CBS 804.70.
21. An isolated DNA sequence which encodes the lipolytic enzyme of any of claims 1-9.
22. An isolated, lipolytic enzyme encoding DNA sequence which comprises:
- a) the DNA sequence shown in positions 114-713 of SEQ ID NO: 2, positions 133-738 of SEQ ID NO: 5 or positions 161-763 of SEQ ID NO: 7, or
 - b) an analogue of the DNA sequence defined in a) which
 - i) is at least 60% homologous with said DNA sequence, or
 - ii) hybridizes with said DNA sequence at 55°C.
23. The DNA sequence of claim 21 or 22, wherein the lipolytic enzyme-encoding sequence is obtainable from a microorganism, preferably a filamentous fungus.
24. The DNA sequence of the preceding claim, wherein the filamentous fungus is a strain of *Gliocladium*, *Verticillium* or *Trichophaea*, preferably the strain *Gliocladium* sp. CBS 173.96, *Verticillium* sp. CBS 173.96 or *T. saccata* CBS 804.70.
25. A recombinant expression vector comprising the DNA sequence of any of claims 21-24.
26. A cell comprising the DNA sequence of any of claims 21-24 or the recombinant expression vector of claim 25.
27. The cell of the preceding claim, which is a eukaryotic cell, in particular a fungal cell, such as a yeast cell or a filamentous fungal cell, preferably a strain of *Aspergillus*, preferably *A. oryzae*.
28. A method of producing a lipolytic enzyme, comprising culturing the cell of any of claims 26-27 under conditions permitting the production of the enzyme, and recovering the enzyme from the culture.
29. A biologically pure culture of a microbial strain which is *Gliocladium* sp. CBS 173.96, *Gliocladium roseum* CBS 126.96 or 127.96 or *Verticillium* sp. CBS 830.95.
30. *Escherichia coli* strain DSM 10591, DSM 10590 or DSM 11298.

Patentansprüche

1. Ein alkalisches lipolytisches Enzym, welches ist:
 - 5 a) ein Polypeptid, das eine Aminosäuresequenz hat, wie gezeigt in den Positionen 1-200 von SEQ ID NO: 3, Positionen 1-202 von SEQ ID NO: 6, oder Positionen 1-201 von SEQ ID NO: 8, oder
 - b) ein Analog des Polypeptids definiert in (a), welches:
 - 10 i) wenigstens 60 % homolog mit besagtem Polypeptid ist, oder
 - ü) immunologisch reaktiv mit einem Antikörper ist, der gegen das besagte Polypeptid in gereinigter Form hergestellt wurde.
2. Das lipolytische Enzym des vorherigen Anspruchs, welches aus einem Mikroorganismus, bevorzugt einem filamentösen Pilz, mehr bevorzugt einem Stamm von *Gliocladium*, *Verticillium* oder *Trichophaea* (vorzugsweise *T. saccata*) erhalten werden kann.
3. Das lipolytische Enzym von Anspruch 2, welches aus einem Stamm von *Gliocladium* erhalten werden kann und eine lipolytische Aktivität bei pH 10 in der Abwesenheit von Ca⁺⁺ von über 20 % der lipolytischen Aktivität bei pH 10 in der Gegenwart von 50 mM Ca⁺⁺ hat.
4. Das lipolytische Enzym von Anspruch 2 oder 3, welches aus einem Stamm von *Gliocladium* erhalten werden kann und das einen Grad an Hydrolyse von über 15 % auf Baumwoll/Olivenöl-Stoffproben im Activity-in-Detergent (AiD) -Test hat.
5. Das lipolytische Enzym von einem der vorherigen Ansprüche, wobei der Stamm *Gliocladium* sp. CBS 173.96 ist oder zu *G. ammoniophilum*, *G. aureum*, *G. catenulatum*, *G. flavum*, *G. nigrovirens*, *G. roseum*, *G. sagariensis* oder *G. solani*, vorzugsweise *Gliocladium* sp. CBS 173.96, *G. ammoniophilum* CBS 156.70, *G. aureum* IFO 9055, *G. catenulatum* NRRL 1091, *G. flavum* CBS 155.27, *G. nigrovirens* CBS 183.30, *G. roseum* CBS 126.96, *G. roseum* CBS 127.96, *G. sagariensis* IFO 9080 oder *G. solani* CBS 707.86 gehört.
6. Das lipolytische Enzym von Anspruch 2, welches aus einem Stamm der Gattung *Verticillium* erhalten werden kann und das mehr als 90 % seiner Aktivität behält nach einer Inkubation für 30 Minuten bei pH 10,2, 40 °C in einer Lösung von 0,300 g/l C14-C16 Alkylsulfat, 0,650 g/l Alkoholethoxylat (C12-C14, 6 EO), 1,750 Zeolith P, 0,145 g/l Na₂CO₃, 0,020 g/l Acrylat/Maleat-Copolymer und 0,050 g/l Carboxymethylcellulose.
7. Das lipolytische Enzym des vorherigen Anspruchs, wobei der Stamm *Verticillium* sp. CBS 830.95 ist.
8. Das lipolytische Enzym von einem der vorherigen Ansprüche, welches Lipase und/oder Cutinase-Aktivität hat.
9. Das lipolytische Enzym von einem der vorherigen Ansprüche in der Gestalt eines enzymatischen Waschmittelzusatzes, welches ein nicht staubendes Granulat ist, eine stabilisierte Flüssigkeit, eine Aufschlämmung, oder ein geschütztes Enzym.
10. Eine enzymatische Waschmittelzusammensetzung umfassend eine oberflächenaktive Substanz und das lipolytische Enzym von einem der vorherigen Ansprüche.
11. Ein Verfahren zum Herstellen eines alkalischen lipolytischen Enzyms, umfassend die Kultivierung eines ein lipolytisches Enzym produzierenden Stammes von *Gliocladium*, *Verticillium* oder *Trichophaea* in einem passendem Nährmedium, gefolgt von Gewinnung des alkalischen lipolytischen Enzyms.
12. Das Verfahren des vorherigen Anspruchs, wobei der Stamm *Gliocladium* sp. CBS 173.96 ist oder zu *G. ammoniophilum*, *G. aureum*, *G. catenulatum*, *G. flavum*, *G. nigrovirens*, *G. roseum*, *G. sagariensis* oder *G. solani*, vorzugsweise *Gliocladium* sp. CBS 173.96, *G. ammoniophilum* CBS 156.70, *G. aureum* IFO 9055, *G. catenulatum* NRRL 1091, *G. flavum* CBS 155.27, *G. nigrovirens* CBS 183.30, *G. roseum* CBS 126.96, *G. roseum* CBS 127.96, *G. sagariensis* IFO 9080 oder *G. solani* CBS 707.86 gehört.
13. Das Verfahren von Anspruch 11, wobei der Stamm ein Stamm von *Verticillium* ist, und vorzugsweise *Verticillium* sp. CBS 830.95 ist.

14. Das Verfahren von Anspruch 11, wobei der Stamm ein Stamm von *Trichophaea* ist, vorzugsweise *T. saccata*, am meisten bevorzugt *T. saccata* CBS 804.70.
15. Ein Verfahren zum Herstellen eines alkalischen lipolytischen Enzyms umfassend:
- a) Isolieren einer DNA-Sequenz kodierend für das lipolytische Enzym eines ein lipolytisches Enzym produzierenden Stammes von *Gliocladium*, *Verticillium* oder *Trichophaea*,
 - b) Kombinieren des DNA-Fragmentes mit geeignetem/geeigneten Expressionssignal(en) in einem geeigneten Vektor,
 - c) Transformieren eines geeigneten heterologen Wirtsorganismus mit dem Vektor,
 - d) Kultivieren des transformierten Wirtsorganismus unter Bedingungen, die zur Expression des lipolytischen Enzyms führen, und
 - e) Gewinnen des lipolytischen Enzyms aus dem Kulturmedium.
16. Das Verfahren des vorherigen Anspruchs, wobei der Wirtsorganismus eine eukaryotische Zelle ist, insbesondere eine Pilzzelle, wie zum Beispiel eine Hefezelle oder eine filamentöse Pilzzelle, vorzugsweise ein Stamm von *Aspergillus*, mehr bevorzugt *A. oryzae*.
17. Das Verfahren von Anspruch 15 oder 16, wobei die DNA-Sequenz mit einem Verfahren isoliert wird, umfassend:
- a) Klonieren, in geeignete Vektoren, einer cDNA-Bibliothek aus einem ein lipolytisches Enzym produzierenden Stamm von *Gliocladium*, *Verticillium* oder *Trichophaea*,
 - b) Transformieren passender Hefewirtszellen mit besagten Vektoren,
 - c) Kultivieren der transformierten Hefewirtszellen unter geeigneten Bedingungen, um das alkalische lipolytische Enzym zu exprimieren,
 - d) Screening nach positiven Klonen durch Bestimmen der lipolytischen Enzymaktivität, die in Schritt (c) exprimiert wird.
18. Das Verfahren von einem der Ansprüche 15-17, wobei der das lipolytische Enzym produzierende Stamm *Gliocladium* sp. CBS 173.96 ist, oder zu *G. ammoniophilum*, *G. aureum*, *G. catenulatum*, *G. flavum*, *G. nigrovirens*, *G. roseum*, *G. sagariensis* oder *G. solani*, vorzugsweise *Gliocladium* sp. CBS 173.96, *G. ammoniophilum* CBS 156.70, *G. aureum* IFO 9055, *G. catenulatum* NRRL 1091, *G. flavum* CBS 155.27, *G. nigrovirens* CBS 183.30, *G. roseum* CBS 126.96, *G. roseum* CBS 127.96, *G. sagariensis* IFO 9080 oder *G. solani* CBS 707.86 gehört.
19. Das Verfahren von einem der Ansprüche 15-17, wobei der das lipolytische Enzym produzierende Stamm zu *Verticillium* gehört, und vorzugsweise *Verticillium* sp. CBS 830.95 ist.
20. Das Verfahren von einem der Ansprüche 15-17, wobei der das lipolytische Enzym produzierende Stamm zu *Trichophaea* gehört, vorzugsweise *T. saccata*, am meisten bevorzugt CBS 804.70.
21. Eine isolierte DNA-Sequenz, welche für das lipolytische Enzym von einem der Ansprüche 1-9 kodiert.
22. Eine isolierte DNA-Sequenz, welche für ein lipolytisches Enzym kodiert, welches umfasst:
- a) die DNA-Sequenz gezeigt in Positionen 114-713 von SEQ ID NO: 2, Positionen 133-738 von SEQ ID NO: 5 oder Positionen 161-763 von SEQ ID NO: 7, oder
 - b) ein Analog der DNA-Sequenz definiert in a) welche
 - i) mindestens 60 % homolog ist mit besagter DNA-Sequenz, oder
 - ii) mit besagter Sequenz bei 55°C hybridisiert.
23. Die DNA-Sequenz von Anspruch 21 oder 22, wobei die für das lipolytische Enzym kodierende Sequenz aus einem Mikroorganismus erhalten werden kann, vorzugsweise einem filamentösen Pilz.
24. Die DNA-Sequenz des vorherigen Anspruchs, wobei der filamentöse Pilz ein Stamm von *Gliocladium*, *Verticillium* oder *Trichophaea* ist, vorzugsweise der Stamm *Gliocladium* sp. CBS 173.96, *Verticillium* sp. CBS 173.96, oder *T. saccata* CBS 804.70.

25. Ein rekombinanter Expressionsvektor umfassend die DNA-Sequenz von einem der Ansprüche 21-24.
26. Eine Zelle umfassend die DNA-Sequenz von einem der Ansprüche 21-24 oder den rekombinanten Expressionsvektor von Anspruch 25.
- 5 27. Die Zelle des vorherigen Anspruchs, welche eine eukaryotische Zelle ist, insbesondere eine Pilzzelle, wie z.B. eine Hefezelle oder eine filamentöse Pilzzelle, vorzugsweise ein Stamm von *Aspergillus*, vorzugsweise *A. oryzae*.
- 10 28. Ein Verfahren zum Herstellen eines lipolytischen Enzyms, umfassend das Kultivieren der Zelle von einem der Ansprüche 26-27 unter Bedingungen, die die Produktion des Enzyms erlauben und Gewinnen des Enzyms aus der Kultur.
- 15 29. Eine biologisch reine Kultur eines mikrobiellen Stammes, welcher *Gliocladium* sp. CBS 173.96, *Gliocladium roseum* CBS 126.96 oder 127.96 oder *Verticillium* sp. CBS 830.95 ist.
30. *Escherichia coli*-Stamm DSM 10591, DSM 10590 oder DSM 11298.

Revendications

- 20 1. Enzyme lipolytique alcaline qui est :
- 25 a) un polypeptide ayant une séquence d'acides aminés telle qu'indiquée aux positions 1 à 200 de SEQ ID N° 3, aux positions 1 à 202 de SEQ ID N° 6, ou aux positions 1 à 201 de SEQ ID N° 8, ou
 b) un analogue du polypeptide défini en (a) qui :
- i) est à au moins 60% homologue au dit polypeptide, ou
 ii) est immunologiquement réactif avec un anticorps dirigé contre ledit polypeptide sous forme purifiée.
- 30 2. Enzyme lipolytique selon la revendication précédente, qui est susceptible d'être obtenue à partir d'un microorganisme, de préférence un champignon filamenteux, plus préférablement une souche de *Gliocladium*, *Verticillium* ou *Trichophaea* (de préférence *T. saccata*).
- 35 3. Enzyme lipolytique selon la revendication 2, qui est susceptible d'être dérivée d'une souche de *Gliocladium* et a une activité lipolytique à pH 10 en l'absence de Ca⁺⁺ au dessus de 20% de l'activité lipolytique à pH 10 en présence de 50 mM de Ca⁺⁺.
- 40 4. Enzyme lipolytique selon la revendication 2 ou 3, qui est susceptible d'être dérivée d'une souche de *Gliocladium* et donne un degré d'hydrolyse au dessus de 15% sur des échantillons coton/huile d'olive dans le test Activité dans le Détergent (AID).
- 45 5. Enzyme lipolytique selon l'une quelconque des revendications précédentes, dans laquelle la souche est *Gliocladium* sp. CBS 173.96 ou appartient à *G. ammoniophilum*, *G. aureum*, *G. catenulatum*, *G. flavum*, *G. nigrovirens*, *G. roseum*, *G. sagariensis* ou *G. solani*, de préférence *Gliocladium* sp. CBS 173.96, *G. ammoniophilum* CBS 156.70, *G. aureum* IFO 9055, *G. catenulatum* NRRL 1091, *G. flavum* CBS 155.27, *G. nigrovirens* CBS 183.30, *G. roseum* CBS 126.96, *G. roseum* CBS 127.96, *G. sagariensis* IFO 9080 ou *G. solani* CBS 707.86.
- 50 6. Enzyme lipolytique selon la revendication 2, qui est susceptible d'être dérivée d'une souche du genre *Verticillium* et conserve plus de 90% d'activité après 30 minutes d'incubation à pH 10,2, 40°C dans une solution de 0,300 g/l de sulfate d'alkyle en C₁₄ à C₁₆, 0,650 g/l d'éthoxylate d'alcool (C₁₂ à C₁₄, 6 EO), 1,750 zéolite P, 0,145 g/l de Na₂CO₃, 0,020 g/l de copolymère acrylate/maléate et 0,050 g/l de carboxyméthylcellulose.
7. Enzyme lipolytique selon la revendication précédente, dans laquelle la souche est *Verticillium* sp. CBS 830.95.
- 55 8. Enzyme lipolytique selon l'une quelconque des revendications précédentes, qui a une activité lipase et/ou cutinase.
9. Enzyme lipolytique selon l'une quelconque des revendications précédentes, sous la forme d'un additif détergent enzymatique qui est un granulé sans poudrage, un liquide stabilisé, une bouillie ou une enzyme protégée.

10. Composition détergente enzymatique comprenant un surfactant et l'enzyme lipolytique selon l'une quelconque des revendications précédentes.
- 5 11. Procédé de production d'une enzyme lipolytique alcaline, comprenant la culture, dans un milieu nutritif approprié, d'une souche de *Gliocladium*, *Verticillium* ou *Trichophaea*, productrice d'enzyme lipolytique suivie de la récupération de l'enzyme lipolytique alcaline.
- 10 12. Procédé selon la revendication précédente, dans lequel la souche est *Gliocladium* sp. CBS 173.96 ou appartient à *G. ammoniophilum*, *G. aureum*, *G. catenulatum*, *G. flavum*, *G. nigrovirens*, *G. roseum*, *G. sagariensis* ou *G. solani*, de préférence *Gliocladium* sp. CBS 173.96, *G. ammoniophilum* CBS 156.70, *G. aureum* IFO 9055, *G. catenulatum* NRRL 1091, *G. flavum* CBS 155.27, *G. nigrovirens* CBS 183.30, *G. roseum* CBS 126.96, *G. roseum* CBS 127.96, *G. sagariensis* IFO 9080 ou *G. solani* CBS 707.86.
- 15 13. Procédé selon la revendication 11, dans lequel la souche est une souche de *Verticillium*, et est de préférence *Verticillium* sp. CBS 830.95.
14. Procédé selon la revendication 11, dans lequel la souche est une souche de *Trichophaea*, de préférence *T. saccata*, le plus préférablement *T. saccata* CBS 804.70.
- 20 15. Procédé de production d'une enzyme lipolytique alcaline, comprenant :
- a) isoler une séquence d'ADN codant pour l'enzyme lipolytique à partir d'une souche de *Gliocladium*, *Verticillium* ou *Trichophaea* productrice d'enzyme lipolytique,
- 25 b) combiner le fragment d'ADN avec un signal ou des signaux d'expression approprié(s) dans un vecteur approprié,
- c) transformer un organisme hôte hétérologue approprié avec le vecteur,
- d) cultiver l'organisme hôte transformé sous des conditions menant à l'expression de l'enzyme lipolytique, et e) récupérer l'enzyme lipolytique à partir du milieu de culture.
- 30 16. Procédé selon la revendication précédente, dans lequel l'organisme hôte est une cellule eucaryote, en particulier une cellule fongique, telle qu'une cellule de levure ou une cellule de champignon filamenteux, de préférence une souche d'*Aspergillus*, plus préférablement *A. oryzae*.
- 35 17. Procédé selon la revendication 15 ou 16, dans lequel la séquence d'ADN est isolée selon un procédé comprenant :
- a) cloner, dans des vecteurs appropriés, une librairie d'ADNc de la souche de *Gliocladium*, *Verticillium* ou *Trichophaea* productrice d'enzyme lipolytique,
- b) transformer des cellules de levure hôtes appropriées avec lesdits vecteurs,
- 40 c) cultiver les cellules de levure hôtes transformées sous des conditions appropriées pour exprimer l'enzyme lipolytique alcaline,
- d) cribler pour les clones positifs en déterminant l'activité enzyme lipolytique exprimée à l'étape c).
- 45 18. Procédé selon l'une quelconque des revendications 15 à 17, dans lequel la souche productrice d'enzyme lipolytique est *Gliocladium* sp. CBS 173.96 ou appartient à *G. ammoniophilum*, *G. aureum*, *G. catenulatum*, *G. flavum*, *G. nigrovirens*, *G. roseum*, *G. sagariensis* ou *G. solani*, de préférence *Gliocladium* sp. CBS 173.96, *G. ammoniophilum* CBS 156.70, *G. aureum* IFO 9055, *G. catenulatum* NRRL 1091, *G. flavum* CBS 155.27, *G. nigrovirens* CBS 183.30, *G. roseum* CBS 126.96, *G. roseum* CBS 127.96, *G. sagariensis* IFO 9080 ou *G. solani* CBS 707.86.
- 50 19. Procédé selon l'une quelconque des revendications 15 à 17, dans lequel la souche productrice d'enzyme lipolytique appartient à *Verticillium* et est de préférence *Verticillium* sp. CBS 830.95.
20. Procédé selon l'une quelconque des revendications 15 à 17, dans lequel la souche productrice d'enzyme lipolytique appartient à *Trichophaea*, de préférence *T. saccata*, le plus préférablement CBS 804.70.
- 55 21. Séquence d'ADN isolée qui code pour l'enzyme lipolytique selon l'une quelconque des revendications 1 à 9.
22. Séquence d'ADN isolée qui code pour une enzyme lipolytique, laquelle séquence comprenant :

- a) la séquence d'ADN indiquée aux positions 114 à 713 de SEQ ID NO : 2, aux positions 133 à 738 de SEQ ID NO : 5 ou aux positions 161 à 763 de SEQ ID NO : 7, ou
b) un analogue de la séquence d'ADN définie en a) qui

- 5 i) est à au moins 60% homologue à ladite séquence d'ADN, ou
 ii) s'hybride avec ladite séquence d'ADN à 55°C.
- 10 23. Séquence d'ADN selon la revendication 21 ou 22, dans laquelle la séquence codant pour l'enzyme lipolytique est susceptible d'être obtenue à partir d'un microorganisme, de préférence un champignon filamenteux.
- 15 24. Séquence d'ADN selon la revendication précédente, dans laquelle le champignon filamenteux est une souche de *Gliocladium*, *Verticillium* ou *Trichophaea*, de préférence la souche *Gliocladium* sp. CBS 173.96, *Verticillium* sp. CBS 173.96 ou *T. saccata* CBS 804.70.
- 20 25. Vecteur d'expression recombinant comprenant la séquence d'ADN selon l'une quelconque des revendications 21 à 24.
- 25 26. Cellule comprenant la séquence d'ADN selon l'une quelconque des revendications 21 à 24 ou le vecteur d'expression recombinant selon la revendication 25.
- 30 27. Cellule selon la revendication précédente, qui est une cellule eucaryote, en particulier une cellule fongique, telle qu'une cellule de levure ou une cellule de champignon filamenteux, de préférence une souche d'*Aspergillus*, plus préférablement *A. oryzae*.
- 35 28. Procédé de production d'une enzyme lipolytique, comprenant cultiver la cellule selon l'une quelconque des revendications 26 à 27 sous des conditions permettant la production de l'enzyme, et récupérer l'enzyme de la culture.
- 40 29. Culture biologiquement pure d'une souche microbienne qui est *Gliocladium* sp. CBS 173.96, *Gliocladium roseum* CBS 126.96 ou 127.96 ou *Verticillium* sp. 830.95.
- 45 30. Souche d'*Escherichia coli* DSM 10591, DSM 10590 ou DSM 11298.
- 50
- 55




FIG. 1: Gliocladium sp. NN140631




FIG. 2: *G. solani* NN102998




FIG. 3: *G. roseum* NN141784




FIG. 4: *G. aureum* NN102987




FIG. 5: *G. roseum* NN141961




FIG. 6: *Verticillium* sp. CBS 830.95




FIG. 7: *T. saccata* CBS 804.70




FIG. 8: *Verticillium* sp. CBS 830.95